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Abstract 
Tissue engineering approaches that are inspired in the hierarchical nanostructure of the 
bone have shown that this structure presents a higher reactivity and functional improvement 
when compared to microsized materials. Nanophase ceramics, especially nano-hydroxyapatite 
(nano-HA), are widely used for bone regeneration and/or replacement in many biomedical 
applications due to their great chemical similarity with bone and teeth and their documented 
ability to promote mineralization. Therefore, there is a strong interest for the syntheses of 
synthetic extra pure and well defined hydroxyapatite nanocrystals. 
Fluidinova, Engenharia de Fluidos S.A, has developed and patented a novel continuous 
reactor, NETmix®, for nano-hydroxyapatite manufacture. This Netmix® technology allows the 
production of the nanoXIM•Hap102®. This product is a highly pure nanocrystalline 
hydroxyapatite in paste form, at 15% (weight/volume) in pure water, with promising features 
for bone regeneration. 
This work aims to study the biological profile of the commercially available preparation 
nanoXIM•HAp102® regarding relevant cellular and molecular events involved in the 
proliferation/differentiation of human Mesenchymal Stem Cells (hMSCs). 
Initially, a preliminary experiment was performed in order to select the appropriate 
concentration range of nano-HA to be tested in mesenchymal stem cells. Thereby, the dose-
dependent effects of nano-HA were investigated in MG63 cells cultured for 7 days in the 
presence of nano-HA in the concentration range 1-1000 μg/mL, by evaluating the metabolic 
activity/cell proliferation by the MTT assay. Results of this preliminary experiment allowed to 
select the concentrations 1, 10, 50 and 100 µg/mL to evaluate the effect of nano-HA in 
hMSCs.  
The response of hMSCs to nano-HA was characterized at days 7, 14 and 21 for cell 
viability/proliferation, histochemical staining of alkaline phosphatase (ALP) and collagen, 
apoptosis and expression of osteoblastic genes. In addition, cultures were observed by 
scanning electron microscope (SEM), confocal laser scanning microscopy (CLSM) and 
transmission electron microscopy (TEM). 
The cell culture experiments showed negligible cytotoxicity of nano-HA in the range 1 - 50 
µg/mL. In addition, the presence of nano-HA at 10 µg/mL caused an increase in the cell 
viability/proliferation, accompanied by the synthesis of ALP and collagen and a normal F-
actin cytoskeleton organization, without any increase in the apoptosis rate. Moreover, hMSCs 
were able to increase the expression of BMP-2. The presence of higher nano-HA levels (50 and 
100 g/mL) were associated with slight deleterious effects in the measured cell response 
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parameters. TEM analyses revealed that nano-HA was readily internalized by hMSCs by 
endocytosis. Nano-HA aggregates were seen in varying size lysosomes and showed low 
intracellular dissolution rate.  
In conclusion, these data contribute to further understanding of the functional properties 
of the nano-HA formulation NanoXIM•HAp102®. Accordingly, nano-HA was able to modulate 
the proliferation and osteoblastic differentiation of hMSCs. At selected conditions, nano-HA 
exhibits an interesting profile for bone tissue applications. 
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Resumo 
Abordagens de engenharia de tecidos que são inspiradas na nanoestrutura hierárquica do 
osso têm mostrado que esta estrutura apresenta uma maior reatividade e desempenho 
funcional quando comparada com materiais micrométricos. Cerâmicos nanofásicos, 
especialmente a nano-hidroxiapatite (nano-HA), são amplamente usados na regeneração e 
/ou substituição óssea em muitas aplicações biomédicas, devido à sua grande similaridade 
química com o osso e os dentes; e devido à sua capacidade para promover a mineralização. 
Neste contexto, existe grande interesse em sintetizar hidroxiapatite sintética extra pura e 
com nanocristais bem definidos. 
A “Fluidinova, Engenharia de Fluidos S.A”, desenvolveu e patenteou um novo reator  
contínuo, NetMix®, para a fabricação de nano-hidroxiapatite. Esta tecnologia, NetMix®, 
permite a produção da nanoXIM•Hap102®. Este produto é uma hidroxiapatite nanocristalina 
de elevada pureza, comercializada na forma de pasta aquosa (15% peso/volume), com 
características promissoras para regeneração óssea. 
Este trabalho tem como objetivo estudar o perfil biológico da preparação comercial 
nanoXIM•HAp102® relativamente a eventos celulares e moleculares pertinentes, envolvidos na 
proliferação e diferenciação osteoblástica de células estaminais mesenquimais humanas 
(hMSCs). 
Inicialmente, foi realizada uma experiência preliminar com o objetivo de selecionar a 
gama de concentração apropriada de nano-HA a ser testada nas hMSCs. Desse modo, os 
efeitos dose-dependentes da nano-HA foram investigados em células osteoblásticas MG63, 
cultivadas durante 7 dias na presença de nano-HA na gama de concentrações de 1-1000 
µg/mL, por avaliação da actividade metabólica/proliferação celular através do ensaio de 
MTT. Os resultados desta experiência preliminar permitiram determinar as concentrações de 
1, 10, 50 e 100 µg/mL para avaliar o efeito da nano-HA em hMSCs. 
A resposta das hMSCs à nano-HA foi caracterizada nos dias 7, 14 e 21 para a viabilidade 
celular/proliferação, coloração histoquímica da fosfatase alcalina e do colagénio, apoptose e 
expressão de genes osteoblásticos. Além disso, as culturas foram observadas por microscópia 
electrónica de varrimento, microscopia confocal de varrimento a laser e microscopia 
electrónica de transmissão. 
Os resultados dos estudos celulares mostraram uma toxicidade mínima da nano-HA na 
gama 1 - 50 µg/mL. Além disso, a presença de 10 µg/mL nano-HA causou um aumento na 
viabilidade/proliferação celular, acompanhado pela síntese de fosfatase alcalina e de 
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colagénio, e por uma organização normal da actina-F do citoesqueleto, sem qualquer 
aumento na taxa de apoptose. Observou-se ainda um aumento na expressão de BMP-2. A 
presença de níveis mais elevados (50 and 100 g/mL) causou um ligeiro efeito citotóxico, 
considerando os parâmetros avaliados. A observação das culturas por microscopia eletrónica 
de transmissão mostrou que a nano-HA foi rapidamente internalizada por um processo de 
endocitose. Observou-se a presença de agregados de nano-HA nos lisossomas, que mostraram 
uma taxa baixa de dissolução intracelular.   
Em conclusão, este estudo contribui para uma melhor compreensão das propriedades 
funcionais da formulação NanoXIM•HAp102®. Assim, a nano-HA apresentou capacidade de 
modular a proliferação e a diferenciação osteoblástica de células mesenquimais humanas. Em 
condições apropriadas, a nano-HA exibe um perfil interessante para aplicações no tecido 
ósseo.  
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Chapter 1  
 
Introduction 
In bone regeneration, the success of using materials with nanosized features, namely 
hydroxyapatite (HA), comparatively to microstructure materials, is considerable. These 
nanomaterials can be used as nanocomposites containing dispersed nanosized calcium 
phosphate (CaP) and, also, as simple nanoscale grains [1]. The reason for the success of 
nanomaterials in bone applications is because they display unique physical and chemical 
properties. Decreasing material size into the nanoscale, it dramatically increases surface 
area, surface roughness and surface area to volume ratios [1-3]. Thus, these materials 
represent an increasingly important material in the development of novel materials which 
can be used in numerous applications.  
When a material is implanted in the bone tissue, the osteointegration process is 
influenced by the properties of the material surface (as topography and chemistry), that have 
the ability to modulate the molecular and cellular events at the implant interface. 
Nanomaterials with surface properties similar to the bone are undoubtedly appropriate for 
the bone regeneration and, therefore, are expected to improve orthopaedic/dental implant 
efficacy [4]. 
Nanophase ceramics, especially nano-hydroxyapatite (nano-HA), are widely used for bone 
regeneration and/or replacement in many biomedical applications due to their documented 
ability to promote mineralization [2]. Synthetic HA is a CaP with the chemical formulae 
Ca10(PO4)6(OH)2, which is similar to the principal inorganic constituent of bone and teeth 
[3,5].  
Synthetic nano-HA can be produced using two routes, i.e. dry and wet methodologies. 
Fluidinova has a new technology to produce nano-HA, the NETmix® technology. By this 
technology, the Fluidinova developed and patented an industrial process based on the wet 
chemical reaction for controlling, at the molecular level, the calcium and phosphate reaction 
to produce HA nanoparticles [6], thus creating a novel product - nanoXIM•Hap102®. This 
product provides promising features for bone regeneration, as bone tissue engineering 
strategies might involve the use of synthetic nano-HA and precursor cells with the ability to 
differentiate into the osteogenic lineage. 
 Chapter 1 
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1.1 - Thesis Objectives and Layout  
For bone regeneration has been increasing much investigation for materials to replace 
bone defect over last decades. This thesis aims to study biological profile of the commercially 
available preparation nanoXIM•HAp102® regarding relevant cellular and molecular events 
involved in the proliferation/differentiation behaviour of human Mesenchymal Stem Cells 
(hMSCs). 
 This synthetic HA, in a paste form, is the focus of this work, as the HA nanoparticles 
present in this paste are a very promising material for bone regeneration strategies [6]. In 
this context, the main objective of the work described in this thesis is to acquire information 
on the interaction of these nano-HA particles with human mesenchymal stem cells, which is 
essential to their application in bone tissue engineering. Therefore, it is intended to obtain 
integrated information on the uptake and intracellular fate of HA nanoparticles by hMSCs and 
the elicited cell response regarding proliferation and differentiation events. 
The layout of the present work is divided as follows. In Chapter 2 the state-of-the-art, on 
the prospective use of nano-HA in bone regeneration and, also, to overview the most recent 
developments in this field. Moreover, it reports the relevant cellular processes occurring in 
bone tissue during normal metabolism and regeneration events, as well as general 
background on mesenchymal stem cells, which can be used to study the suitability of a 
material for bone regeneration approaches. In summary, the contents addressed have a 
fundamental aim to provide background for a rational intervention in this work.  
The experimental methodology is described in Chapter 3. Results are presented in 
Chapter 4, and discussed in Chapter 5. Finally, the general conclusions drawn from this work 
are presented in Chapter 6. 
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Chapter 2  
 
Literature Review 
2.1 - Tissue engineering 
Tissue engineering is an emerging field of interdisciplinary science and research that 
encompass several scientific areas such as medicine, biochemistry and materials science. It 
generally involves the use of materials and cells with goal of trying to understand tissue 
function and restore of damage tissues. In summary, it aims at developing new approaches 
for encouraging tissue growth and repair. [7-10] 
Nowadays, there are several bone pathological conditions that might require the use of 
biomaterials to restore bone structure and function, such as bone fracture, osteoporosis, and 
bone cancer, among others. However, traditional implant materials may be associated with 
several complications, namely failures originating from implant loosening, inflammation, 
infection, osteolysis and wear debris. Bone tissue engineering has a major role in bone repair 
approaches, particularly by using nanotechnology, which becomes obvious when examining 
nature. [2] 
With the entry of the nanotechnology in the field of regenerative medicine, there are 
many developments of nanostructured biomaterials, which have the ability for guiding 
cellular behaviour by presenting specific morphological and biological cues [1].  
Accordingly in bone tissue engineering, one of the main interests is the development of 
novel nanomaterials with appropriate mechanical properties and, also, biomimetic in terms 
of their nanostructure [1-3].  
Therefore, bone tissue engineering develops new approaches inspired by the hierarchical 
nanostructure of bone. This approach intends to obtain adequate synthetic nanomaterials 
(such as calcium material bioceramics) that should ideally be biocompatible, osteocondutive, 
osteoinductive, osteogenic, and biodegradable, leading to osteointegration [1]. 
 
 Chapter 2 
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2.2 - Bone  
2.2.1 - Bone function  
Bone is a living conjunctive tissue in permanent growth, since throughout life it is 
constantly removed and replaced [11]. It has the mechanical function of providing 
attachment for muscles, facilitating the locomotion process, and it provides structural 
support for the other systems and organs [11-13]. Furthermore, bone is considered as a 
reservoir of calcium, phosphate and other inorganic ions [14].  
 
2.2.2 - Bone composition 
Bone is a composite material, constituted by bone cells dispersed in a bone matrix, which 
has an organic and a mineral component. The organic part of this matrix is mainly composed 
of fibrillar collagen type I (~90%) and noncallagenous proteins (10%) such as osteonectin, 
osteocalcin, osteopontin, bone sialoprotein, proteoglycans, glycoproteins, enzymes (e.g. 
alkaline phosphatase) and cytokines [1, 15]. The mineral phase of mature bone tissue is 
composed by calcium and phosphate. This phase has many similarities to the synthetic 
hydroxyapatite (HA), which has the chemical structure Ca10(PO4)6(OH)2 [3]. The bone mineral 
phase also contains other ions, such as carbonate, citrate, sodium, magnesium, fluoride, 
hydroxyl, potassium and others that can be found in smaller amounts [15, 16]. 
 
2.2.3 - Bone Structure 
The morphological structure of the bone can be classified as cancellous (spongy or 
trabecular bone) and as cortical (compact or dense bone) [11]. Both types of bone exist in 
different proportions in several locations of de skeleton.  
The compact bone is dense and it is located on the external parts of the bone. Its main 
function is to provide strength, it is relatively acellular and it has low metabolic activity [17]. 
Cortical bone is organized in cylindrical units, Haversian systems also known as osteons, 
which forms the diaphysis of long bones [15]. The Haversian systems are surrounded by a 
concentric layer of rings or lamellae [13, 15]. In the inner of the lamellae there are tiny 
spaces called lacunae containing bone cells, the osteocytes [13]. These units are considered 
the structural units of this type of bone. Osteons are typically circular or oval in cross 
section, 20 to 110 µm in diameter, and contain central canals with blood vessels to provide 
nutrition, lymph vessels and occasionally nerves [11, 13, 17]. The intercommunicating pore 
systems, constituted by canaliculi, lacunae and Volksmann’s canals which connect with 
Haversian canals, allow the transport of metabolic substances [15, 17]. 
Cancellous bone is porous and it is sited in the interior of bone. In general, cancellous 
bone is more closely associated with metabolic processes [11, 15]. It is found in the epiphysis 
of bone and this type of bone is lamellar in structure. The microstructure of cancellous bone 
shows interconnecting rods or occasionally plates of bone called trabecular [11, 13]. 
Cancellous bone is arranged as open cell porous networks that allow the transport of 
metabolic substances [15]. 
Literature Review 
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The periosteum is the membrane that covers bone external surface, not including the 
articulating joints. It consists of an outer fibrous layer containing collagen fibres and 
fibroblasts and an inner layer that contains the osteogenic cells [12, 13, 18]. The inner 
surface of the bone is covered by a thin membrane called the endosteum. This membrane is 
found facing the medullary cavity. The endosteum contains a single layer of cells and a small 
amount of connective tissue [18]. Both lining membranes, periosteum and endosteum, 
contain osteoblasts and their progenitor cells [13]. 
 
2.2.4 - Bone cells 
Bone tissue is dynamic organ undergoing constant remodelling. This is possible to the 
important role of bone cells.  These cells are responsible for producing, maintaining and 
modifying the bone tissue in order to maintain its mechanical and structural properties [11]. 
There are four types of cells in bone tissue: osteoblasts, bone lining cells, osteocytes, and 
osteoclasts (figure 1) [11, 18]. Osteoblasts, osteoclasts and bone lining cells, that are located 
on the bone surfaces, and osteocytes, that can only be found in the interior of the 
mineralized extracellular matrix (ECM) [11]. 
 
Figure 1 - The origins and locations of bone cells (Adopted from Downeyet et. al 2006). 
 
2.2.4.1 - Osteoblast 
Osteoblasts are mononuclear and differentiated cells, with low mobility and their 
function is to synthesize the bone matrix and regulate the mineralization of the osteoid [15, 
19]. Therefore, the osteoblasts are responsible for bone building because they play an active 
role in the synthesis of the proteins and polysaccharides of the bone matrix [20]. When 
active, osteoblasts have a characteristic morphology, since they have a marked cytoplasmic 
basophilia, round nuclei rich in ribonucleic acid located at the base of the cell opposite to 
the bone surface, contain large quantities of rough endoplasmic reticula, and the Golgi 
apparatus is a well visible, features typical of a protein producing cell [21-23].  
Osteoblasts, during their lifetime, have several fates. They can follow one of three 
pathways: (1) remain active osteoblasts, (2) become surrounded by matrix and become 
osteocytes, or (3) transform into the relatively inactive bone lining cells [21, 24]. Briefly, 
osteoblasts may disappear by transformation into either bone-lining cells or osteocytes, or 
even by apoptosis mechanisms [20]. 
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The osteoblast cells originated from undifferentiated mesenchymal stem cells (MSCs) that 
have the potential to become osteoblasts. MSCs are found in bone canals, endosteum, 
periosteum and marrow [11, 21, 25]. The undifferentiated cells remain in this state until they 
are stimulated to proliferate and differentiate into the osteoblast, thus MSCs behave as a 
pre-osteoblast, and they can migrate from neighbouring tissues or through the vascular 
system up to a target site [11, 21, 22, 26]. The osteogenic cells, MSCs, can be induced to 
differentiate into osteoblasts producing a bone like matrix by the synthetic glucocorticoid, 
dexamethasone, or by the bone morphogenic proteins (BMPs) [27].  Differentiation of MSCs 
into osteoblast cells is controlled by the regulated expression of genes that define three main 
periods of osteoblast phenotype development (proliferation, extracellular matrix (ECM) 
development and maturation, and mineralization). During proliferation, several ECM proteins, 
such as histone H4 and type I collagen (Col I) can be detected in this stage. Expression of 
alkaline phosphatase (ALP) is an earlier marker of the matrix maturation phase, while the 
expression of osteopontin (OP) and osteocalcin (OC) is found in the late maturation or early 
mineralization phases [23, 27]. 
 
Figure 2 - The relationship between cell growth and differentiation-related gene expression during 
development in culture of the osteoblast phenotype: histone H4, COL I, ALP, OP, OC. The three 
principal stages of the osteoblast developmental are shown: proliferation, ECM development and 
maturation, and mineralization. (Adopted from Lian et. al 1995).  
 
2.2.4.2 - Bone lining cells 
Bone lining cells are inactive osteoblasts with flat appearance that cover most of the 
surface area of the normal bone [11, 21]. These cells are considered to be in communication 
with osteocytes and are found linked to each other, through cytoplasmic extensions or gap 
junctions [21].  
The functions of the bone lining cells include the protection of the bone from the 
extracellular fluids, maintaining the bone own environment, the response to mechanical 
forces on the skeleton [21, 24] and, also, to several hormones, playing a role in the bone 
remodelling events [11, 20-22]. In addition, they are involved in mineral homeostasis, namely 
in the exchange of calcium and phosphorus ions into and out of the bone [11, 20]. 
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2.2.4.3 - Osteocytes 
The osteocytes are mature bone cells, and are the main cells in bone tissue (>90%) [11, 
18, 21, 22, 24]. These bone cells are spidery in shape with a plump cell body and reside in a 
lacuna, and the slender cytoplasm processes that radiate from osteocytes are found in 
canaliculi [11, 21]. In general, the osteocytes are surrounded by bone matrix, thus they have 
small nuclei, scanty cytoplasm with mitochondria and a small Golgi zone indicating their low 
activity compared to the osteoblasts [11, 22]. An osteocyte may derive from the osteoblast 
that became embedded in its own osteoid [11]. 
The function of this cell is to maintain the bone tissue, being involved in the exchange of 
nutrients and wastes with the blood. Like osteoblasts, osteocytes do not undergo cell 
division. [18]~ 
 
2.2.4.4 – Osteoclasts 
The osteoclasts are multinucleated giant cells differentiated from the 
monocyte/macrophage lineage, wherein are formed to carry out the unique function of bone 
resorption under both normal and pathological conditions. [11, 13, 21]. Once the osteoclasts 
are derived from a monocyte stem-cell lineage, they are equipped with phagocytic-like 
mechanisms similar to circulating macrophages. So, following osteoclast attachment to the 
bone surface, bone degradations begins by direct chemical and enzymatic attack [12]. 
Morphologically, the osteoclast can have several forms because they have a high mobility, 
moving from various sites and along the bone surface [21]. In general, these cells are found 
at the surface of bone and they may be much larger than other bone cells, because they 
might contain up to 50 nuclei [11, 21].   
 
2.2.5 - Bone remodelling, healing and repair 
Bone is constantly being remodelled by the highly regulated bone resorption and forming 
actions of the osteoclasts and osteoblasts, respectively [11, 13]. Thus, the bone is found 
throughout life in remodelling, i.e. bone has a continuous shaping. As the old bone is 
removed, new bone is produced to replace it, and calcium ions are released for other tissues 
[11, 18]. 
The processes involved in the bone replacement, bone reabsorption and bone formation, 
are regarded as independent events, but according to Frost [28] that described the sequential 
activities of bone replacement, they are closely linked spatially, in an anatomical and 
temporal sequence, to ensure a balance in the removal of mineralized matrix and the bone 
replacement [11, 29]. The anatomical structure is named basic multicellular unit (BMU), and 
this structure describes the sequential activities of osteoclasts and osteoblasts during 
remodelling [29]. 
In the process of bone reabsorption, the osteoclasts adhere strongly to the bone surface 
at the endosteum or periosteum, and releases protein-digesting lysosomal enzymes and 
several acids into the sealed surface. Thereby, the collagen fibres and other organic 
substances are digested by enzymes, while the acids dissolve the bone minerals. The 
degradation products of the bone, mainly calcium and phosphorus, go to the bloodstream by 
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exocytosis. Thus, bone remodelling occurs when the small area removed by the osteoclasts is 
rebuilt by the osteoblasts [18]. 
The remodelling rate for compact bone is about 4% per year, and for spongy bone it is 
about 20% per year [18, 30]. However, the bone remodelling can also take place at different 
rates in different regions of the body [30]. 
The bone remodelling process allows the removal and the repair of bone microdamage, 
the adaptation to mechanical stress and the maintenance of its strength and integrity [18, 
31]. Furthermore, the skeletal remodelling maintains the mineral ion homeostasis. 
Remodelling is regulated and stimulated by a number of hormones, such as vitamin D, 
parathyroid hormone, calcitonin and estrogen [24].   
Injury in the bone, such as a fracture or the implant replacement, results in the loss of 
continuity of bone tissue, and it is associated to the damage of the blood vessels. 
Consequently, haemorrhage occurs and there is the formation of a blood clot, or hematoma 
[33]. Healing of bone tissue provides the capacity to repair the tissue continuity, form and 
function with a mechanism scar free [34, 35]. Bone tissue has a potential to heal itself, 
resulting in the regeneration of the anatomy of the bone and complete function. 
The bone repair process is very complex, because it involves the coordination and 
sequence of many biological events [35, 36]. Bone healing can be divided into four phases: 
blood clotting, inflammatory phase, reparative phase and remodelling phase [34-36].  
Once the bone tissue injury leads to damage to surrounding tissues, the bone healing is 
initiated by the activation of the coagulation cascade and by the formation of the blood clot 
[35, 36]. The blood clot allows the cellular migration and proliferation; furthermore, it 
functions as a primary source of growth factors [34]. Thus, inflammatory cells are recruited, 
such as neutrophils, macrophages, monocytes, lymphocytes, and cells of other lineages, such 
as fibroblasts and endothelial cells. Then, recruitment of the cells is followed by an acute 
inflammatory response resulting in the edema and cytokine and growth factor release [36]. 
The healing process continues by the reparative phase with resorption of the blood clot 
and its replacement by the deposition and formation of granulation tissue [34]. In this phase, 
there is vascular growth and migration of osteogenic cells. The granulation tissue is 
responsible for providing blood supply and for the recruitment of undifferentiated 
mesenchymal stem cells. At the lesion site, these cells proliferate and differentiate because 
they responded to growth factors released by the injured tissues and from the clot [3]. 
Finally, after 6 to 8 weeks, bone tissue is completely remodelled in the original shape, 
structure, function and mechanical properties [34, 35]. 
2.3 - Bone marrow and stromal cells 
Bone marrow is a very complex organ, and it is composed by stromal tissue, 
hematopoietic cords and sinusoidal capillaries [36, 37]. The stromal tissue supports 
haematopoiesis and is made up of a network of extracellular matrix and cells [36, 38, 39]. 
Furthermore, stromal tissue has well known osteogenic potential [40]. 
Bone marrow stromal cells are widely used in tissue engineering [40, 41]. These cells are 
a heterogeneous population of non-hematopoietic cells of mesenchymal origin and 
fibroblastic cells [36, 40, 41]. Other cells are present in this population, such as monocytes, 
macrophages and endothelial cells [36, 40]. Following the culture of bone marrow stromal 
cells, the non-adherent cells are removed after medium change and cell passage [41]. 
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Included in the adherent cell population, the mesenchymal stem cells (MSCs) are multipotent 
cells widely used in tissue engineering. 
 
2.3.1 - Mesenchymal Stem Cells 
The MSCs have the capacity of self-renewal and they are defined as a type of adult stem 
cells which contribute, in some circumstance, to the regeneration of mesenchymal tissues, 
once they can produce progeny that differentiate across the three primary germ layers 
(ectoderm, mesoderm and endoderm) [36, 42, 43]. Human MSC are easy to isolate from small 
aspirate of bone marrow via their adherence ability and they can be easily expanded in vitro 
[39]. 
MSCs that can give rise to mature cells, and in defined in vitro conditions, these cells 
readily differentiate to multiple connective tissue lineages, including osteoblasts, 
chondrocytes, and adipocytes [39, 43].  
The morphology of the MSCs is characterized by a small cell body with a few cell 
processes that are long and thin. Furthermore, MSCs have a nucleus with prominent nucleolus 
which is surrounded by finely dispersed chromatin particles, giving the nucleus a clear 
appearance [20].  
These cells are widely used in tissue engineering, because the selection of the culture 
conditions and the subsequent manipulations allow defining cell differentiation.  
 
2.3.2 - Osteogenic differentiation potential of MSCs 
The in vitro expansion of MSCs has been extensively studied by tissue engineering owing 
to their potential to differentiate into osteogenic tissue. The osteoblastic behaviour of MSCs 
in culture is normally achieved by culturing in an appropriate standard cell culture medium 
(i.e., α-minimum essential medium with 10% foetal bovine serum) supplemented with β-
glicerophosphate, ascorbic acid and dexamethasone [27, 44-46]. Under these conditions, the 
MSCs in culture acquire an osteoblastic morphology and differentiate along the osteogenic 
phenotype, being able to express typical osteoblastic genes and to form a collagenous 
mineralized matrix [45, 46]. 
 
2.3.2.1 - Gene expression of MSCs during osteogenic differentiation 
The MSCs have a potential to generate many cellular lineages such as osteogenic, 
adipogenic or chondrogenic cell lineage [47, 48]. The differentiation of MSCs into a cell 
lineage is dependent on the activated signalling pathways and several transcription factors 
[13, 47, 49, 50].  
The transcriptional factors runt related protein 2 (Runx-2), osterix and β-catenin are 
essential to regulate the differentiation of MSCs into osteoblast lineage [47]. 
Osteoblast commitment and differentiation are guaranteed by Runx-2, it is responsible for 
inducing the osteogenic phenotype at an early stage and also to inhibit the differentiation of 
MSCs into adipocytes and chondrocytes [13, 47, 49, 51]. Runx-2 is known to activate and up-
regulate the expression of major bone matrix protein genes of osteoblast differentiation, 
such as type I collagen (Col I), osteopontin (OP), bone sialoprotein (BSP) and osteocalcin (OC) 
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[47, 49, 52]. Therefore, this transcriptional factor allows cells acquiring an osteoblast 
phenotype, although keeping the osteoblast cells in an immature stage, the preosteoblast 
[47, 49]. Preosteoblast proliferation and differentiation follows distinct phases: 
preosteoblast, mature osteoblast, and osteocyte, which are regulated by transcription factors 
and express specific phenotypic genes [53]. 
Other factors can regulate the activity of specific transcription factors maintaining an 
osteoblastic fate. They include bone morphogenetic proteins (BMPs) that are recognized for 
their osteoinductive proprieties, and regulate the differentiation of MSCs into osteoblasts 
components of bone [49]. Furthermore BMP-2 and wingless-ints (Wnts) pathways together 
have a critical role in promoting Runx-2 expression to promote osteoblast differentiation [13, 
51]. 
The osteoblastic phenotype is characterized by the synthesis of specific bone proteins 
that define a genic expression pattern. The gene markers expression of osteoblast allows 
defining the distinct stages of osteoblast phenotype development: proliferation, matrix 
maturation and mineralization. In each stage there are characteristic changes in gene 
expression [49, 54, 55].  
As already mentioned, in an early stage during the proliferative phase, there is the 
expression of genes that support the proliferation, such as Col I and fibronectin [23, 27, 49, 
56]. However, in this phase, BMP-2 and BMP-5 have a significant role in increasing ALP 
activity and OC synthesis [49]. So, the accumulation of these matrix proteins allows, in part, 
the end of cell proliferation.  The differentiation stage is recognized by early cell 
differentiation that is characterised by the transcription and expression of the ALP [56]. 
Thereby, these markers are widely used to evaluate the osteogenic differentiation.  
Ultimately, the ECM becomes into the mineralization phase in which osteoblastic cell express 
osteopontin (OP) and osteocalcin (OC). These protein markers are found in the late 
maturation or early mineralization phases [23, 27, 49]. 
Osteoblasts produce osteoprotegerin (OPG) which is a soluble decoy receptor for the 
receptor activator of nuclear factor kappa B ligand (RANKL), and it is known that the major 
effect of OPG is to inhibit osteoclastogenesis [50, 57].  However, its role in osteoblast 
differentiation is still unclear. More recently, Yu et al. (2011) showed that OPG expression is 
associated with preosteoblast maturation and promotes matrix maturation [57]. 
In a study on osteoblast behaviour or osteogenic differentiation of MSCs it is very 
important to analyse the gene expression profile of the cells. The interest in analysing the 
RNA is explained by a cell’s ability to adjust its mRNA copy numbers in response to 
environmental changes, being a crucial element in the complex regulation of gene 
expression. Moreover, at the mRNA level, it is known that a wide spectrum of pathological 
processes is associated with changes in gene expression [58]. 
The reverse transcription-polymerase chain reaction (RT-PCR) is a powerful tool for gene 
expression analysis. This technique is a PCR method that uses reverse transcriptase enzymes 
for making DNA from RNA [59]. The RT-PCR combines synthesis of the cDNA with its 
amplification allowing the cloning of genes from its mRNA. Thereby, this technique allows the 
analysis of the gene expression [59]. The result obtained from RT-PCR analysis allows to know 
whether a specific gene is being express into a cell [59]. 
The PCR method is characterized by the ability of DNA polymerase enzyme to synthetize a 
new strand of complementary DNA. The PCR reaction requires: a biological sample that 
contains DNA or RNA; a DNA polymerase enzyme; some salts for the DNA polymerase to 
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function; deoxynucleotide triphosphates (dNTPS) which provide essential nucleotides for new 
DNA strands; and finally oligonucleotides primers, which are responsible for initiating the 
chain reaction, being extremely specific to the precise genetic sequence of interest [59-61]. 
After PCR reaction, the reaction components are placed into a thermocycler, where they 
undergo basic PCR steps [59]. The PCR procedure involves repeated cycles of three steps, 
namely heat denaturation, annealing, and primer extension [59, 62]. 
In the first step, the thermocycler drives the reaction components up to denaturation 
temperature, typically 92 to 94°C. The denaturation allows that the hydrogen bonds of the 
double DNA helix are broken, and thereby the DNA double helix is reduced into single strands 
[59, 62].  
In the next step, the temperature of the mixture decreased to a predetermined annealing 
temperature, usually between 50 and 60°C. In this step of PCR, the oligonucleotide primers 
can hybridise specifically to their complementary sequences, meaning that the primers can 
anneal to the DNA target sequence [59, 62]. 
Finally, the replication of the DNA strands occurs. After the annealing step, the 
temperature is raised to 72°C, and a DNA polymerase extends the primers by incorporating 
deoxynucleotides to form a new complementary strand of DNA [59, 62]. 
The cycle denaturation-annealing-extension is repeated over and over, usually 30 times, 
and new strands themselves as template for the DNA primers and the process lead to an 
exponential amplification of the DNA bounded by the primers [59, 61, 62]. These cycles allow 
an estimated enrichment of the selected sequence of 105 to 106 [61]. 
After the termination of the reaction cycles, the reaction products are separated by 
agarose gel electrophoresis, and finally they can be visualized directly by staining with 
ethidium bromide and examination of the gel under ultraviolet light [61].  
An important aspect to take into consideration when analysing PCR results is that several 
parameters need to be controlled to obtain reliable quantitative expression measures. To 
this, it is often used an approach for the normalization of several parameters with an internal 
control gene. A gene valid to use as a reference gene requires an expression that do not vary 
in the tissues or cells under certain experimental conditions [48, 63]. One example of the 
most usually described normalization gene is glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). This gene is present in most cell types and it is considered a simple “housekeeping” 
protein that has been shown to be involved in many cellular processes in addition to 
glycolysis, where its function is catalysing the reversible oxidative phosphorylation of 
glyceraldeyade-3-phosphate [48, 63, 64]. 
2.4 - Nanomaterials in bone regeneration 
Nanomaterials can be defined as the materials with dimensions less than 100 nm [1, 2, 
65]. These materials include nanoparticles, nanoclusters, nanocrystals, nanotubes, 
nanofibres, nanowires, nanorods, nanofilms, etc. [2] 
Nanomaterials are promising candidates in bone regeneration, since nanostructure 
provides a closer approximation to native bone architecture, compared to micron materials 
[2, 66].The decreasing material size leads to modification of the nanofeatured surfaces, 
increased surface area, surface roughness and surface to volume ratio, which creates superior 
physiochemical properties to the cellular behaviour [2, 66]. For example, increase of surface 
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energy and wettability, seen in nanostructured surfaces, allows to an increased protein 
adsorption and cell adhesion [66, 67].  
Recently, more efforts are being made to repair and reconstruct bone damage using 
biomimetic bone tissue. To accomplish this, it is necessary to select biomaterials that are 
present in bone (e.g. HA and collagen), and it is also possible to incorporate growth factors 
(e.g. BMPs) and/or cells for bone repair and regeneration [66]. 
Based on the structure of the natural HA, nano-HA has been synthesized for various tissue 
engineering applications, such as for bone replacement and for the delivery of relevant drugs 
in the management of several bone diseases [68]. Furthermore, many studies revealed that 
biomimetic nano-HA enhances the proliferation and activity of bone cells in the regeneration 
process compared to the microstructured ceramic [67, 69-72]. Webster et al. (2000) showed 
that cell differentiation markers, such as alkaline phosphatase (ALP) synthesis and calcium 
deposition, were significantly greater on nanophase HA than on conventional ceramic [73]. 
 
2.4.1 - Hydroxyapatite 
Bioceramics materials, namely calcium phosphate (CaP)-based materials, are widely used 
for bone regeneration and/or replacement in many biomedical applications. Synthetic HA is a 
CaP with the chemical formulae Ca10(PO4)6(OH)2, and a Ca/P ratio of 1.67, which is similar to 
the principal inorganic constituent of bone and teeth [3,5] . However, CaP can also exist with 
a Ca/P ratio lower than 1.67, referred as calcium-deficient hydroxyapatite (DHA), denoted by 
Ca10-x (HPO4)x(PO4)6-x(OH)2-x [5, 73, 74]. HA (Ca/P=1.67) has been extensively investigated 
because it is a thermodynamically stable CaP in the physical environment [3] and shows 
excellent biological characteristics, due to its natural biocompatibility and potential 
osteoconductive, osteoinductive, osteogenic and biodegradable properties [1, 69]. 
 
2.4.1.1 - Nanostructured and properties  
HA is a polycrystalline CaP, with a definite crystallographic structure. The hexagonal 
crystalline structure of HA allows exact atomic positions, and this structure have a space 
group P63/m. This space is characterized by a six-fold c-axis perpendicular to three 
equivalent a-axes at 120◦ angles to each other. Calcium cations (Ca2+) and phosphate anions 
(PO4
3-) are arranged around columns of monovalent hydroxyl anions (OH-) [3, 76, 77]. Figure 3 
shows the unit of HA, composed by Ca, PO4 and OH groups closely packed together. Also, it 
can be noted that PO4 group provides the skeleton framework and gives the structure and its 
stability [78]. 
HA is a mineral with small nanosized dimensions and low crystallinity, properties that 
provide distinct features of the biological apatites. The synthetic HA can be synthesized using 
many processes. Crystallographic and chemical studies have confirmed that synthetic HA is 
similar to the natural HA found in bone and teeth [1, 77]. Therefore, the synthetic HA is 
widely used for bone regeneration and/or replacement in many biomedical applications.  
Besides the similarities of the synthetic HA and natural HA, there are more advantages for 
its application in tissue engineering. Thus, synthetic HA shows biocompatibility, slow 
biodegradability in situ, and good osteoconductive and osteoinductive capabilities [1, 69, 79-
81].  
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Figure 3 - Unit of hydroxyapatite hexagonally crystalline structure. (Adopted from White et. al 2009). 
The nanophase HA powders show improved properties when compared with microphased 
powders, such as surface grain size, pore size and wettability, which may control protein 
interactions and thus guide cellular responses. Therefore, the nano-HA has a better 
bioactivity [3, 81], hence it allows a good osteoblast adhesion, proliferation, differentiation , 
osteointegration, and deposition of calcium-containing minerals on its surface, leading to an 
improvement of the composition of regenerated tissue within a short period [67,69-72,82].  
In summary, according to the literature, nano-HA appears to have clear advantages in 
bone regeneration applications [83]. 
 
2.4.1.2 - Synthesis Methods  
The nano-HA is an important material in bone regeneration, therefore there is a strong 
interest in its synthesis in an extra pure and well defined HA nanocrystals [20].  
Several techniques have been developed to prepare nanosized HA, most of them involving 
wet and dry methods. 
The dry methods for nano-HA synthesis are characterized by the preparation of the 
powder via application of high temperature, high-energy mechanical and controlled pressure. 
In this process, calcium and phosphorous compounds are used as reactants. These powders 
are mixed in acetone, calcinated in vacuum and, lastly, heat-treated with the supply of 
water vapour as the source of the hydroxyl group [1, 85]. The reactants used in the dry 
process can be several calcium and phosphorous compounds such as, dicalcium phosphate 
anhydrous (CaHPO4), dicalcium phosphate dihydrate (CaHPO4.2H2O), monocalcium phosphate 
monohydrate (Ca(H2PO4)2.H2O) , calcium pyrophosphate (Ca2P2O7), calcium carbonate 
(CaCO3), calcium oxide (CaO) and calcium hydroxide (Ca(OH)2), among others [85]. 
The wet chemical precipitation method (i.e. wet chemical precipitation, sol-gel, 
emulsion, biomimetics, among others) is widely used because it is significantly cheaper and 
easier than other methods of HA formation [1, 3, 74] and the probability of contamination 
during processing is very low [85]. Thus, this technique is more popular for synthesis nano-HA 
since, no specialized equipment is required and large quantities of material can be produced 
of nanostructured HA from aqueous solution [1, 3, 74].  
The reaction of Yagai and Aoki (1) can be followed in order to obtain suspensions of HA 
nanoparticles. A solution of H3PO4 is dropped into a basic suspension of Ca (OH)2 [1, 69, 86]. 
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Other calcium compounds may be used to obtain suspensions of nanoparticles. For 
example, calcium nitrate tetrahydrate (Ca(NO3)2.4H2O can be added to ammonium 
dihydrogen phosphate (NH4H2PO4)[1, 69]. 
In the wet chemical precipitation method, it is important that the reactants have the 
correct molar ratio of calcium and phosphorous and, also, to adjust and maintain the 
appropriate pH of the solution [87]. 
Synthesis of nano-HA by wet chemical precipitation allows controlling the particle shape, 
size and specific surface area, by monitoring the reactant addition rate, reaction 
temperature, pH, and the presence of additives [1, 69]. In literature, the crystallinity of HA is 
largely increases by reaction temperature [1, 69, 88]. 
 
2.4.1.3 - NETmix® Technology 
The NETmix® is a novel technology (development at FEUP) that enables the production of 
nanomaterials, such as nano-HA, with a high reproducibility, mainly in terms of size 
distribution [4]. This technology is now being commercially applied by Fluidinova to the 
synthesis of highly pure hydroxyapatite nanoparticles, nanoXIM-HAp® [5, 15, 89]. 
The NETmix® is a patented static mixer, on continuous mode operation [89] for mixing of 
liquids and/or gases; it allows the control of fluid mixture in an optimized and reproducible 
way. [90] Furthermore, this technology shows reproducible and satisfactory results, 
especially with regard to distribution of particle sizes [91]. 
Its principal component is a network of chambers interconnected by channels, that is, the 
network combines, in an organized manner, chambers and channels [92]. This 
interconnection create zones that promote complete mixing and of complete segregation, as 
shown in figure 4 [5]. 
The implementation of the static mixer brought improvements in comparison with other 
static systems. For example, its structure is considerably simple; it allows the introduction of 
temperature, pressure and concentration sensors; it provides an easy implantation of 
different pre-mixing reactants injection schemes; it has the ability to control the mean 
residence time of the reactants and the mixing intensity and scale. Thus, this reactor is 
particularly suitable for reactions in which mixing quality and intensity are critical. [92] 
 
Figure 4 - Regular network of the reactor NETmix® in an association chambers and channels. (Adopted 
from Silva et. al 2008). 
 
The NETmix® regulates micromixing; this phenomenon is associated to the 
homogenization of the mixture at the smallest scale [92, 93]. The properties of the HA 
produced by NETmix®, such as purity, crystallinity, particle size distribution, crystallites size 
and morphology, can be determine by the micromixing characteristics [74].  
Literature Review 
15 
 
In the laboratory, the prototype of this technology, consisting of a network of spherical 
chambers and cylindrical channels, was developed and used for the synthesis of nano-HA with 
high reproducibility, mainly in terms of size distribution [5]. The NETmix® reactor, for the 
synthesis of nano-HA, is based on the wet chemical precipitation method at room 
temperature [89].  
Therefore, to produce nano-HA is necessary to feed the reactor with a calcium solution, a 
phosphorous solution and an alkaline solution and, optionally, one solvent or dispersing agent 
[74]. The initial reactants are injected in inlet chambers through the back and front feeding 
channels (figure 5). 
 
Figure 5 - Representation of the feed system NETmix® reactor. (1) Feeding channels; (2) inlet 
chambers; (A-F) reagents inlet. (Adopted from Faria et. al 2008). 
 
The products synthesized by this technology can be collected in the form of suspension at 
the exit or the intermediate position of the reactor. Then, the suspension can be subjected 
to a separation process in order to concentrate the particles. Moreover, the concentrated 
particles can be washed for the elimination of the supernatant, and they can be exposed to 
drying processes. Thereafter, the particles may be subjected to several stages of grinding and 
thermal treatments. [89]  
From its versatile technology, NETmix® Fluidinova is responsible by launching several 
products with a single phase and high purity, such as the nanoXIM•HAp102®. This product is a 
highly pure nanocrystalline hydroxyapatite in paste form at 15% (weight/volume) nano-HA 
concentration in pure water.  
In summary, the NETmix® technology results from the application of a novel concept for 
producing HA nanoparticles, based on wet chemical precipitation method at room 
temperature. This patented industrial process is able of controlling, at the molecular level, 
the calcium and phosphate reaction to produce HA nanoparticles [6, 74, 94]. 
 
2.4.1.4 - Applications 
Synthetic nanosized HA is the most stable CaP and it has been used for a variety of 
biomedical applications, such as in dentistry, matrices for drug release control and surgery 
for hard tissue repair [1, 3, 77, 95]. The previous studies have been so far mostly used owing 
to its chemical similarity to the mineral component of calcified tissue [3, 5, 95]. In addition, 
other properties have attracted interest, such as their high surface area, their ability to 
become dispersed in aqueous solutions and their higher reactivity and adsorption, over the 
same material of micrometric size [2]. 
Nano-HA is a bioactive ceramic that has been preferred for hard tissue repair and as 
coatings for metal prosthesis over autografts and allografts. For some time now, it appears 
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that synthetic HA increases the response regarding bone bonding. Accordingly, the nano-HA is 
used as an implant coating to stimulate bone growth around the implant. [3, 96] 
Many studies have demonstrated that the mechanical strength and fracture toughness of 
HA can be improved by the use of nanoscale powders; the large surface area to volume ratios 
of the particles contributed for a better densification [76]. Accordingly, nano-HA can be used 
to produce scaffolds for tissue engineering, and when nano-HA is compressed, for example 
into a cylinder, it has attracted interest for bone replacement [3, 97]. 
The nano-HA particles with high surface area and un-agglomerated are of interest for 
injectable or controlled setting bone cements, high strength porous or non-porous synthetic 
bone grafts and the reinforcing phase in nanocomposites that attempt to mimic the complex 
structure and superior mechanical proprieties of bone [98]. Furthermore, the nano-HA has 
been widely used in dentistry. Huang et al., [99] for example, showed that nano-HA had the 
potential to remineralize initial enamel caries lesions. 
Recently, many researchers have interest in using the magnetic nano-HA, since it is 
possible to couple HA with magnetic particles such as cobalt (Co), iron (Fe) and magnetite 
(Fe3O4) [3, 77]. This magnetic coupling aims at particle delivery by external control of a 
magnetic field. The magnetic HA composites are adapted for biological applications such as 
cell separation, drug delivery, contrast agents for magnetic resonance imaging (MRI), and 
heat mediators for hyperthermia [3, 100]. Moreover, other studies suggested that nano-HA 
coated magnetic particles could be used to reverse osteoporosis [101-103], once osteoblast 
density and osteoblast differentiation markers are significantly increased in the present HA-
coated-Fe3O4 [102]. 
2.5 - Interactions cells – Nanostructured materials 
Nanostructured materials for bone applications have the ability to improve surface 
reactivity, because surface area-to-volume ratios increase with decreasing particle size [1, 
104]. According to literature, the surface properties (such as surface area, charge, and 
topography) are related to the grain size of a material, thus the cell response to the 
nanoparticles is significantly different that the one observed during the cell interaction with 
the bulk materials [66, 68, 104, 105].  
In particular, for cell interaction it is beneficial if the surface roughness of HA is in the 
nanoscale range but the reasons for this improvement are not completely understood. [3] 
However, it is believed that protein adsorption and bioactivity on particles with nanometer 
features is different from that on conventional materials. Interaction between cells and 
nanostructured materials also depends on receptors on the cell surface and the protein layer 
adsorbed onto the material surface [3]. It is reported that the adsorption and conformation 
(or bioactivity) of proteins that mediate specific osteoblast adhesion (such as fibronectin and 
vitronectin) are enhanced on nanophase material [67, 84, 73]. 
Several studies on the cell response to HA nanoparticles have shown that HA particles are 
internalized through endocytosis, and the cell response appears to depend on the combined 
interaction of multiple nanoparticles characteristics [5, 68, 106-108]. An important aspect in 
the modulation of the cell behaviour is that the HA nanoparticles may be digested in the 
lysosomes, leading to an increase of the levels of Ca2+ in the cytoplasm. Suitable 
concentration of Ca2+ is favourable for the proliferation and osteoblast differentiation [109]. 
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2.5.1 - Apoptosis 
Investigation of the cell-material interaction is mainly focused on biocompatibility. 
However, nowadays much attention is given to the possibility of apoptosis induced by 
biomaterial, once apoptosis could be caused by inducing factors, and many disease therapies 
are closely related to inducing apoptosis. 
Apoptosis is recognized by an important mode of programmed cell death, which involves 
the genetically determined elimination of cells. It is a homeostatic mechanism responsible for 
the maintenance of normal cellular homeostasis [110, 111]. Moreover, this process can occur 
as a defence mechanism against cellular damage caused by disease or noxious agents. [110, 
111] In other words, this phenomenon can be activated or inhibited by several stimuli, both 
physiological and pathological [111].  
It is important to note that there are other forms of cell death, such as, necrosis, and 
other forms may be discovered. Moreover, there are cells that die with atypical 
characteristics, which are not categorized as apoptosis or necrosis [112].  
Apoptosis contrasted with necrosis. Necrosis is considered to be a toxic process 
characterized by loss of cell membrane integrity leading to the release of the cytoplasmic 
contents, which causes the recruitment of inflammatory cells. Once apoptotic cells do not 
release the cytoplasmic contents and apoptotic cells or cell fragments are quickly 
phagocytized they have a little or no immune response [112].  
Apoptosis can be considered a coordinated and often energy dependent process that 
involves caspase activity, DNA fragmentation and a complete cascade of events [110, 1110, 
113]. 
Caspases are a family of cysteine aspartate-specific proteases that have a critical role in 
biochemical events associated with apoptosis [114, 115]. In particular, the activation of 
caspase-3 protease has been described as an “effector” caspase associated with the initiation 
of the “death cascade” and is therefore an important marker of the cells when they are into 
apoptotic signalling pathway [116].  
Nowadays, there are many methods to determine apoptosis in cells through the 
evaluation of the activity of proteins involved in apoptosis. Note that when there is the 
activation of caspase-3 there is substrate specificity for the amino sequence aspartate-
glutamate-valine-aspartate. Thereby, the substrate can be used to continuously monitor the 
activity of caspase-3. Upon enzymatic cleavage, the nonfluorescent substrate is converted in 
a two-step process to a fluorescent compound. So, this is the base for caspase-3 activity 
assay that detect apoptotic events [110,112]. This assay requires cell lysis, which aims to 
release the enzyme into solution, followed by detection with a fluorescent labelled substrate 
with the appropriate excitation and emission settings [110,112]. Detection of caspases 
represents a rapid and consistent method for quantification of apoptotic cells [110,112].  
Another form to analyse cell apoptosis is through morphological characteristics 
observation of the cells by standard transmission electron microscopy (TEM).  This technique 
allows to define characteristics of an apoptotic cell, such as intact cellular membranes, dark 
and dense cytoplasm and nucleus, blebs at the cell surface, large clear vacuoles, 
disorganized cytoplasmic organization and nuclear fragmentation [110-112]. Thereby, TEM is 
used to confirm apoptosis once the categorization of apoptotic cells is irrefutable in case the 
cell contains certain morphological characteristics of an apoptotic cell [111, 112].
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Materials and Methods 
3.1 - NanoXIM•HAp102® 
NanoXIM•HAp102® is a new nanoparticle formulation which is provided by Fluidinova, 
Engenharia de Fluídos S.A. It was obtained by NETmix® technology. This synthetic product is a 
highly pure nanocrystalline HA in past form at 15% (weight/volume) in pure water. This paste 
is formed by nanocrystals of HA with an aspect ratio of 1:10 (Annex 1), and a size typically 
less than 100 nm, as determined by high resolution transmission electron microscopy (TEM). 
This synthetic hydroxyapatite has a stoichiometric ratio of Ca/P=1.67±1%. 
The NanoXIM•HAp102® is characterized as having a single hydroxyapatite phase. This is a 
particularly relevant characteristic of the quality of nanoXIM•HAp products, verified for 
calcination temperatures of 1000ºC. 
The above information of NanoXIM•HAp102® was obtained from the technical datasheet 
supplied by Fluidinova, which is presented in Annex 1. 
Prior to the biological experiments, HA past was subjected to sterilization by gamma 
radiation.  
3.2 - Pre-test: dose-dependent effect of nano-HA in MG63 
osteoblast-like cells 
A preliminary experiment was performed in order to select the appropriate concentration 
range of nano-HA to be tested in mesenchymal stem cells. The MG63 osteoblast-like cell line 
was used in this experiment.  
MG63 cells were cultured in α-minimal essential medium (α-MEM) (31885-049, Gibco-
Invitrogen) supplemented with 10% (v/v) fetal bovine serum (FBS-MSC Expansion ref. 12662-
029, Gibco-Invitrogen), 1% (v/v) Penicillin/Streptomycin (15140-122, Alfagene), 1% (v/v) 
fungizone (15140-122, Alfagene) and 50 µg/mL ascorbic acid (15140-122, Alfagene), and were 
maintained in a humidified atmosphere with 5% CO2 at 37°C. For subculture, the cell 
monolayer was washed twice with phosphate-buffered saline (PBS) and incubated with 
trypsin–EDTA solution (0.05% trypsin, 0.25% EDTA) for 10 min at 37°C to detach the cells. 
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Then, complete culture medium (2x the volume of trypsin that was used) was added to stop 
the reaction. Cells were re-suspended in culture medium and were seeded at density of 104 
cells/cm2 in 96-well plates. After 24h, the culture medium was removed and replaced by one 
containing nano-HA. The following concentrations were tested: 1, 10, 50, 100, 500 and 1000 
µg/mL. Cultures were maintained for 2, 4 and 7 days, without any medium change. Cultures 
grown in the absence of nano-HA were used as control. This pre-test was conducted with four 
replicates. Dose-effects of nano-HA in MG63 cells were evaluated by the MTT assay, as it is 
described below.  
3.3 - Culture of hMSCs 
hMSCs (P10576, Lonza) were routinely cultured in α-minimal essential medium (α-MEM) 
(31885-049, Gibco-Invitrogen) supplemented with 10% (v/v) foetal bovine serum (FBS-MSC 
Expansion ref. 12662-029, Gibco-Invitrogen), 1% (v/v) Penicillin/Streptomycin (15140-122, 
Alfagene), 1% (v/v) fungizone (15140-122, Alfagene) and 50 µg/mL (v/v) ascorbic acid (15140-
122, Alfagene). Cells were seeded in 90 mm diameter culture plates and were maintained in 
a humidified atmosphere with 5% CO2 at 37°C. When the cells had grown to confluence, they 
were washed three times with sterile PBS, and adherent cells were detached by adding  1mL 
of trypsin (solution of 0.04% trypsin in 0.25% EDTA 25200-056, Gibbo, Invitrogen); cells were 
kept in an incubator (37°C and 5% CO2) for 10 minutes to detach the cells. Then, complete 
culture medium (2x the volume of trypsin that was used) was added to stop the reaction.  
To analyse the effect of nano-HA on the behaviour of hMSCs, 104 cells/cm2 were seeded in 
96-well and 6-well plates. At the 6th day, nano-HA was added to the cultures. Nano-HA was 
tested at the following concentrations: 1, 10, 50 and 100 µg/mL. Cultures performed in the 
absence of nano-HA were used as control. Cultures were maintained for 21 days, and the 
culture medium (which did not contain nano-HA) was changed twice a week. Cultures were 
characterized at days 7, 14 and 21, as described below.  
3.4 - Characterization of the cell cultures 
3.4.1 - Metabolic activity/cell proliferation  
Metabolic activity of hMSCs was evaluated at 3, 6, 7, 14 and 21 days by the MTT assay. In 
this assay, the MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; 
Sigma M2128) is reduced to a formazan product by active mitochondrial dehydrogenases of 
living cells. MTT assay was also performed in wells containing the culture medium with the 
nano-HA (without cells), to be used as “blanks”, to correct for the eventual interferences of 
nano-HA with the MTT assay. Briefly, for the assay, cells seeded on 96-well plates were 
incubated with MTT (0.5 mg/mL), for 3h to allow the formation of formazan crystals. After 
this period, the supernatant was discarded and 150 μl dimethyl sulphoxide (DMSO) 
(131954.1611 1 L, Panreac) was added to dissolve the purple formazan crystals. Then, 100 μL 
of the supernatant were transferred to a RIA plate (96-well plate) and the absorbance was 
read at 550 nm in an ELISA reader (BioTek synergy HT). Results were expressed as absorbance 
values.  
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3.4.2 - Cell morphology and F-actin cytoskeletal organization 
Cytoskeletal organization was followed by F-actin/DNA staining. Cultures were rinsed 
with PBS at 37ºC and were fixed in 3.7% paraformaldehyde (PFA) for 15 minutes at the room 
temperature; PFA was removed and cultures were rinsed twice with PBS. Subsequently, cells 
were permeabilized in 0.2% (V/V) Triton X-100 (Sigma T-8787) in PBS, for 10 minutes at room 
temperature, and then rinsed 3 times with PBS. After, cultures were incubated with 1% (V/V) 
BSA solution in PBS for 1h at room temperature. Following, the samples were incubated with 
Alexa Fluor 488 phalloidin (Molecular Probes A-12379) diluted 1:40 in the BSA/PBS solution, 
for 1h in the dark at room temperature, for the staining of the F-actin filaments. After, the 
samples were washed 3 times with PBS. Cell nuclei were counterstained with propidium 
iodide (P4170-10MG Sigma) diluted 1:10000 in PBS. The samples were incubated with 
propidium iodide solution for 10 minutes at room temperature. The propidium iodide was 
removed washed 3 times with PBS. Finally, samples were covered with Fluoromount™ 
Aqueous Mounting Medium (F4680; Sigma) and remained at 4ºC in the dark until observation. 
Samples were observed by Confocal Laser Scanning Microscopy (CLSM) at days 7, 14 and 21 of 
culture. Images were acquired on a Leica TCP SP2 AOBS microscope.  
 
3.4.3 - Alkaline phosphatase and collagen histochemical staining 
At days 7, 14 and 21 the presence of ALP and collagen in cell cultures was visualized by 
histochemical staining. Cultures were rinsed with PBS at 37ºC and fixed with 1.5% 
glutaraldehyde in 0.14 M sodium cacodylate buffer for 10 min. For ALP staining, cultures were 
incubated in a diluted alkaline solution of Na-α-naphthyl phosphate substrate (N7255-1G, 
Sigma) in tris buffer 0.1 M pH 10 (T-8524, Sigma) containing the Fast Violet RR salt (F-0500, 
Sigma), for 1h in the dark. After staining, the samples were rinsed with water to remove the 
excess of dye. Cells containing ALP on their surface developed a brown to black stain after 
the incubation period. 
For collagen histochemical staining, fixed samples were washed with PBS and left to dry 
in the air. Dried samples were incubated with dye sirius red for 1h at room temperature. This 
dye was prepared in picric acid at a concentration of 100 mg/100 ml. Then, the dye was 
discarded and samples were washed four times with hydrochloric acid 0.01 M to remove the 
excess of dye. Collagen stained red after the incubation period. 
After staining, both samples were observed in a Nikon TMS optical microscope and images 
were captured using Eclipse Net software.  
 
3.4.5 - Transmission electron microscopy (TEM) 
Cultures were observed by transmission electron microscopy (TEM) at days 7, 14 and 21, 
for assessment of morphology characteristics and nano-HA uptake. For this, cultures were 
washed three times with PBS at 37ºC. Then, adherent cells were enzymatically released 
(0.05% trypsin, 0.25% EDTA; 4 minutes) and the cell suspensions were centrifuged at 5000 rpm 
for 10 min. The resulting pellet was fixed in 2.5 % glutaraldehyde for 2h at 4ºC, post fixed 
with 2 % osmium tetroxide, dehydrated in graded ethanol and later embedded in Epon, using 
routine methods. Ultra-thin (100 nm) sections mounted in copper grids (300 Mesh) were 
contrasted with uranyl acetate and lead citrate for TEM analysis (ZeissEM10A) at an 
accelerating voltage 60 kV. 
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3.4.6 - Scanning Electron Microscope (SEM) 
Scanning Electron Microscopy (SEM) was used to analyse the cell morphology and the 
organization of the cell layer.  
Cultures were washed with PBS at 37ºC and they were fixed in 1.5 %(v/v) glutaraldehyde 
in 0.1 M sodium cacodylate solution at RT for 10 min. Fixed samples were washed with PBS 
and stored in cacodilate buffer at 4ºC. Before SEM observation, the fixed samples were dried 
with increasing concentration of alcohols (70, 80, 2 x 90 and 99.8 % v/v), critical-point dried 
and sputter-coated with gold (80%) and palladium (20%) alloy under high vacuum. The 
samples were analyzed in a JeoL JSM 6301F scanning electron microscope equipped with an 
X-ray energy dispersive spectroscopy (EDX) microanalysis capability (Voyager XRMA System, 
Noran Instruments).  
 
3.4.7 - Apoptosis 
Apoptosis was assessed by EnzCk®Caspase-3 assay kit (Molecular Probes) on days 7, 14 and 
21 of culture. The programmed cell death was detected from cell cultures using this kit 
according to manufacturer’s instructions. This technique allows detection of apoptosis by 
assaying for the increase in caspases-3. Initially, cells were washed twice with PBS and then 
lysed with 0.1% (V/V) Triton X-100 for 15 minutes. The supernatants from each sample were 
transferred to 96-well plate black and assayed for caspase-3 activity. The fluorescence was 
measured using an ELISA reader (BioTek synergy HT) with excitation at 485 nm and emission 
at 528 nm. Results were expressed as the amount of fluorescence.  
 
3.4.8 - Gene expression by reverse-transcription polymerase chain reaction 
(RT-PCR) 
Cell cultures were assessed on days 7, 14 and 21 by RT-PCR for the expression of the 
housekeeping gene GAPDH and the osteoblastic genes RUNX 2, Col I, ALP, OPG and BMP-2. 
Total RNA was extracted from cell cultures using NucleoSpin®RNA kit according to 
manufacturer’s instructions. RNA was quantified by measuring the absorbance of the samples 
at 260 nm. RT reaction mixtures consisted of extracted RNA, RT-PCR buffer, dithiothreitol 
(dTT), deoxynucleoside triphosphate (dNTPs), primers sequence forward (PF) and reverse 
(PR) for each gene tested, Taq-DNA polymerase and water in a final volume of 25 µL. The 
complementary DNAs (cDNAs) were then amplified with recombinant Taq-DNA polymerase 
with the Titan One Tube RT-PCR System (Roche) under the following conditions: 30 cycles of 
denaturation (94ºC/30 s), annealing with specific temperature for each gene tested (table I), 
elongation (68ºC/45 s), and followed by a prolonged elongation of 7 min at 68ºC. Table I 
shows the primers sequences and annealing temperatures that were used for PCR 
amplification. The RT-PCR products were electrophoresed on 1% (weight/volume) agarose gel 
and stained with ethidium bromide. The gel pictures were taken with a camera under 
ultraviolet illumination. The area and integrated density (ID) of bands were calculated with 
ImageJ 1.41 software. The ID values obtained were normalized to the corresponding ID value 
of GADPH that served as the internal control. 
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Table.1 - Primers for RT-PCR amplification and optimal annealing temperature 
Gene 5´Primer 3´Primer 
Annealing 
T(ºC) 
GAPDH 5´-CAGGACCAGGTTCACCAACAAGT-3´ 5´-GTGGCAGTGATGGCATGGACTGT-3´ 55 
RUNX 2 5’-CAGTTCCCAAGCATTTCATCC-3’ 5’-TCAATATGGTCGCCAAACAG-3’ 55 
Col I 5´-TCCGGCTCCTGCTCCTCTTA-3´ 5´-ACCAGCAGGACCAGCATCTC-3´ 55 
ALP 5´-ACGTGGCTAAGAATGTCATC-3´ 5´-CTGGTAGGCGATGTCCTTA-3´ 55 
OPG 5’-AAGGAGCTGCAGTACGTCAA-3’ 5’-CTGCTCGAAGGTGAGGTTAG-3’ 60 
BMP-2 5´-GCAATGGCCTTATCTGTGAC-3´ 5´-GCAATGGCCTTATCTGTGAC-3´ 60 
3.5. Statistical analysis 
Results are presented as mean ± standard deviation. Three independent experiments 
were performed. In each experiment, four replicas were set up for the biochemical assays 
and two replicas for the qualitative assays. Statistical differences between control cultures 
and cultures exposed to nano-HA were determined with the non-parametric tests unpaired t 
tests. Differences between groups were considered statistically different for p-values less 
than 0.05 (p< 0.05). Calculations were performed using GraphPad Prism software for Windows 
(version 5.0). 
  
24 
 
  
25 
 
Chapter 4  
 
Results 
4.1 - Pre-test: dose-dependent effect of nano-HA in MG63 
osteoblast-like cells 
Initially, the dose-dependent effects of nano-HA were investigated in MG63 cells cultured 
for 7 days in the presence of nano-HA in the concentration range 1-1000 μg/mL, by evaluating 
the metabolic activity/cell proliferation by the MTT assay. Results are presented in figure 6.  
 
Figure 6 - Metabolic activity/cell proliferation profile of MG63 osteoblast-like cells cultured in the 
presence of different nano-HA concentrations, at days 2, 4 and 7. Nano-HA was added 24h after cell 
seeding. Cell metabolic activity was determined using the MTT assay. The in absence of nano-HA were 
used as control. Results of MTT assays were expressed as means ± standard deviation (SD). Asterisks (*) 
indicate a significant difference (p < 0.05) from control (absence of nano-HA). 
 
In control conditions, values for the MTT reduction increased during the 7-day culture 
period. The presence of nano-HA tended to cause an increase at day 4 (10 and 50 g/mL) and 
at day 7 (1 to 100 g/mL), but this increase did not attain statistical significance. However, 
at the concentration of 1000 µg/mL the metabolic activity/cell proliferation was significantly 
lower than in control at day 7. 
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With this information, the effect of nano-HA in hMSCs was tested for the concentrations 
1, 10, 50 and 100 µg/mL. The response of hMSCs to nano-HA was characterized for cell 
viability/proliferation, DNA quantification, histochemical staining of ALP and collagen, 
apoptosis and expression of osteoblastic genes. In addition, cultures were observed by SEM, 
CLSM and TEM. 
4.2 - Behaviour of hMSCs in the presence of nano-HA  
4.2.1 - Metabolic activity/cell proliferation 
Cell viability/proliferation of hMSCs exposed to nano-HA on different conditions of culture 
was measured by the MTT assay. Results are presented in figure 7. In control conditions 
(absence of nano-HA) cell viability/proliferation increased during the 21-day culture time. 
Nano-HA was added at day 6, and cultures were assessed at days 7, 14 and 21. At day 7 (1 day 
after the addition of nano-HA), there was a tendency for an increase in the presence of 50 
and 100 µg/mL, but this effect did not attain statistical significance. At day 14 (7 days after 
the addition of nano-HA), a dose-dependent decrease was observed, with a statistical 
significant value in the presence of 100 µg/mL nano-HA. However, cultures exposed to the 
lower nano-HA levels were able to recover from this deleterious effect and, at day 21, 
significantly increased values were measured in the cultures exposed to 10 µg/mL. Still, 
exposure to higher levels of nano-HA (50 and 100 µg/mL) cause a decrease in the cell 
viability/proliferation (~38 and 29%). 
 
Figure 7 - Metabolic activity/cell proliferation profile of hMSCs cultured in the presence of different 
nano-HA concentrations at days 7, 14 and 21, assessed by the MTT assay. Nano-HA was added at day 6 
Results were expressed as means ± standard deviation (SD). Asterisks (*) indicate a significant difference 
(p < 0.05) from control (absence of nano-HA).  
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4.2.2 - Alkaline phosphatase and collagen histochemical staining 
Control cultures and cultures exposed to 10 and 50 µg/mL were stained for the presence 
of ALP and collagen, at days 7, 14 and 21 Figure 8 shows a low magnification image (x2) of 
the stained cultures, which allows a better perception for how to hMSCs behaved throughout 
the 21-day culture time. Both control and nano-HA-exposed cultures presented cell clusters 
which increased in size and staining intensity from day 7 to day 21. Compared to control, 
cultures performed in the presence of 10 µg/mL nano-HA showed higher ALP staining at days 
14 and 21 and higher collagen staining at day 21. However, nano-HA, at 50 µg/mL, caused a 
deleterious effect, evident at day 21, as suggested by the presence of small sized cell clusters 
exhibiting low staining intensity. 
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Figure 8 - Low magnification view of hMSCs cultured in the absence (control) and in the presence of 10 
and 50 µg/mL nano-HA, stained for ALP and Collagen, at days 7, 14 and 21. ALP is shown by a brown to 
black stain, and collagen by a red stain. Magnification: 2X.  
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Figure 9 - Images of ALP histochemical staining of hMSCs cultured in the absence (control) and in the 
presence of 10 and 50 µg/mL nano-HA, at days 7, 14 and 21. The presence of ALP is shown by a brown to 
black stain. Magnification: 200 X. Scale bar = 100 µm  
 
Figures 9 and 10 present microscopic images of the cultures stained for ALP and collagen, 
respectively. Histochemical staining increased from day 7 to day 21. Cultures showed a 
typical pattern of cell growth with the presence of cell clusters showing areas of higher cell 
density giving a nodular appearance. These cell clusters stained intensively for ALP and 
collagen. The presence of 10 µg/mL nano-HA caused an increase in the staining intensity at 
day 21. Exposure to 50 µg/mL nano-HA resulted in some loss of the typical pattern of cell 
growth and, apparently, a lower number of adherent cells.  
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Figure 10 - Images of Collagen histochemical staining of hMSCs cultured in the absence (control) and in 
the presence of 10 and 50 µg/mL nano-HA, at days 7, 14 and 21The presence of collagen is shown by red 
to pink stain. Magnification: 200X. 
 
4.2.3 - Scanning Electron Microscope (SEM) 
On SEM observation, figure 11, hMSCs presented a spread appearance with an 
elongated/polygonal morphology, both in control cultures and in the presence of nano-HA (10 
and 50 µg/mL). Cells exhibit long cytoplasmic projections (filopodia) and cell-to-cell 
interactions. In addition, the cell layer increased along the culture time. When the cultures 
exposed to nano-HA, the HA particles appeared to be closely associated with the cell layer, 
suggesting a high affinity between the cells and the HA particles. High magnification SEM 
images, figure 12, shows a detailed view of this interaction. Nano-HA particles appeared as 
different sized agglomerates that appeared to be located over the cell surface and also inside 
the cell. Figure 13A also illustrate this behaviour, showing agglomerates that are placed on 
the cell surface (marked as +) but others that seemed to have a intracellular location (marked 
with an *). 
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Figure 11 - SEM images of hMSCs cultured in the absence (control) and in the presence of 10 and 50 
µg/mL nano-HA, at days 7, 14 and 21. Magnifications: 1000x.  
 
Figure 12 - High magnification SEM images of hMSCs cultured in the presence of nano-HA. (A) Cultures 
exposed to 10 µg/mL, 14 days; (B) cultures exposed to 50 µg/mL, 21 days. Magnification: 5 000 x.  
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EDS analysis was performed in order to confirm the elemental composition of the nano-HA 
agglomerates. Figure 13 (right side). shows the EDS spectra of the particles that were seen in 
the culture substrate (#) and that appeared to be present inside the cell (*), respectively Z1 
and Z3 spectra, indicating that particle’s aggregates contain of calcium, phosphorus and 
oxygen, evidencing the presence of a calcium phosphate compound. The Z2 spectrum shows 
only the peak of the carbon which it is characteristic of the culture substrate. The spectrum 
Z2 was determined in order to confirm that the main elements detected in the Z1 and Z3 
spectrum are not derived from the culture substrate. Figure 13B displays a high magnification 
SEM image of a nano-HA micro agglomerate, showing the individual nanoparticles.  
 
  
 
 
 
Figure 13 - SEM images (left side) and EDS spectra of selected areas (right side). A: detailed view of the 
interaction of hMSCs with the nano-HA (10 µg/mL, day 7), showing particles agglomerates over the 
culture substratum (#), over the cell surface (+) and, apparently, inside the cell (*). B: high 
magnification image of a nano-HA agglomerate showing the individual nanoparticles. Z1, Z2 and Z3: EDS 
spectra of the marked areas in the SEM images. A (backscattered image): Bar = 20 µm; B: Bar = 2 µm. 
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4.2.4 - Cell morphology and F-actin cytoskeletal organization 
 
 
Figure 14 - Confocal laser scanning microscopy images of hMSCs cultured in the absence (control) and in 
the presence of different nano-HA concentrations (1 to 100 µg/mL), at days 7 and 14 (a). High 
magnification images of the control cultures and the cultures exposed to 10 µg/mL nano-HA, at day 14 
(b). Cultures were stained for actin cytoskeletal organization (green) and nuclei (red). Scale bar = 50 
µm. 
Confocal laser scanning microscopy (CLSM) allows the observation of the F-actin 
cytoskeletal organization by staining with fluorescence-labelled phalloidin.  
Trough images obtained by CLSM it is possible to assess cell mobility, cell spreading, and 
cellular morphology. As shown in figure 14 it may be seen that cells displayed an elongated 
morphology in control and nano-HA 10 µg/mL. In fact when hMSCs were exposed to nano-HA 
10 µg/mL showed a normal filamentous morphology and it showed no difference compared 
with control. In contrast, when cells were exposed to nano-HA 50 and 100 µg/mL cells had 
alteration in fibres of cytoskeletal. 
 
4.2.5 - Transmission Electron Microscopy (TEM)  
Cultures of hMSCs performed in the absence (control) and in the presence of nano-HA 
were observed by TEM. Figure 15 shows the TEM images for cultures exposed to nano-HA for 1 
day. Control cells presented the expected morphology for osteoblastic cells, namely a 
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prominent nucleus and a rich endoplasmic reticule (figure 15-A). In the presence of nano-HA, 
a close interaction of the nano-HA aggregates with the cell membrane was observed (figure 
15-B, C). Particles were internalized and were located in lysosomic vesicles (figure 15-D, E). 
Uptake of nano-HA appeared to be dose-dependent, as the cells exposed to 50 µg/mL (figure 
15-E) seemed to have a higher amount of internalized particles compared to dose exposed to 
10 µg/mL (figure 15-D). 
Few cells displaying apoptotic signs were seen in the cultures performed in the presence 
of 50 µg/mL nano-HA (figure 15-F).  
 
  
 
Figure 15 -Transmission electron microscopy images of hMSCs cultured in the absence (control) and in 
the presence of nano-HA, at day 7, i.e. 1 day after the addition of nano-HA. A: control cell; B and C: 
interaction of nano-HA with the cell membrane; D: internalized particles in a cell exposed to 10 µg/mL 
nano-HA; E: internalized particles in a cell exposed to 50 µg/mL nano-HA; F: apoptotic cell found in the 
cultures exposed to 50 µg/mL nano-HA. 
4.2.6 - Apoptosis 
Caspase activity is the hallmark for apoptosis. Thus, hMSCs cultured in the absence 
(control) and in the presence of nano-HA (1 to 100 µg/mL) were assessed for caspase-3 
activity (figure 16).  
A small increase in the amount of caspase-3 was noted in the cultures exposed to 50 and 
100 µg/mL nano-HA, at days 7 and 14 (~16 to 20%). At day 21, values were similar to those on 
control cultures.  
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Figure 16 - Apoptosis profile of hMSCs cultured in the absence (control) and in the presence of nano-HA 
(1 to 100 µg/mL), by the evaluation of the amount of caspase-3, at days 7, 14 and 21. Results were 
expressed as means ± standard deviation (SD). Asterisks (*) indicate a significant difference (p < 0.05) 
from control (absence of nano-HA). 
 
4.2.7. Gene expression by reverse-transcription polymerase chain reaction 
(RT-PCR)  
The interaction of nano-HA with hMSCs was evaluated for the level of gene expression of 
osteoblastic-related proteins, such as Runx-2, Col-1, ALP, BMP-2 and OPG .  
Figure 17 shows that hMSCs expressed the tested genes. Nano-HA did not significantly 
affect the expression of Runx-2, Col-1 and OPG. However, nano-HA, at 10 µg/mL, caused a 
small induction in the expression of BMP-2, at days 7 and 14. In addition, the presence of 
nano-HA, at 50 µg/mL, resulted in a small decrease in the expression of ALP at days 7 and 21. 
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Figure 17 - RT-PCR analyses of hMSCs cultured in the absence (control) and in the presence of nano-HA 10 and 50 µg/mL, at days 7, 14 and 21. Bands of the RT-PCR 
products (A) were subjected to a measurement of the area and integrated density (ID) by ImageJ 1.41 software. The ID values of gene expression were normalized to the 
corresponding GAPDH ID value. The expression profile of hMSCs was evaluated for Runx-2 (B), Col-1 (C), ALP (D), BMP-2 and OPG (F). Results were expressed as means ± 
standard deviation (SD). Asterisks (*) indicate a significant difference (p < 0.05) from control and number sign (#) indicate a significant difference between nano-HA 10 and 
50 µg/mL. 
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Discussion 
For bone applications, nano-HA are promising candidates since this structure provides a 
closer approximation to native bone architecture, compared to micron materials [2, 66]. The 
decreasing material size leads to modification of the nano featured surfaces, increased 
surface area, surface roughness and surface to volume ratio, which creates superior 
physiochemical properties and improved cellular behaviour [1-3, 66, 67, 71]. Thus, strategies 
based in using nanoparticles to treat/fill bone defects can potentially induce bone formation 
[102]. 
The purpose of this investigation was to evaluate the behaviour of hMSCs of a novel 
synthetic nano-HA - nanoXIM•Hap102® - regarding relevant cellular and molecular events 
involved in the proliferation and osteoblastic differentiation pathway throughout a 21day 
culture period. 
In order to define the appropriate concentration range of nano-HA to evaluate the cell 
response, a preliminary dose-dependent study was conducted with MG63 osteoblastic cells 
using a wide concentration range of nano-HA, 1-1000 µg/mL. The osteoblastic cell line MG63 
provides a homogeneous, phenotypically stable and proliferative population and shows many 
phenotypic features of normal osteoblastic cells including hormonal responsiveness and 
expression of early and late stage osteogenic genes. For these characteristics MG63 cells has 
been used extensively as an osteoblast cell model for in vitro research [117, 118]. In fact, in 
the present study, this osteoblast model allowed to assess the dose-effect of nano-HA in the 
cell viability/proliferation in the wide range of 1-1000 μL/mL and in a short time period (7 
days). The results of this preliminary experiment (figure 6) suggested that nano-HA at 
concentration higher than 500 µg/mL caused a dose-dependent inhibitory effect on cell 
metabolic activity/proliferation. This observation is in concordance with that reported in a 
previous study, also using MG63 cells, showing that HA nanoparticles with a similar 
morphology caused deleterious effects on osteoblastic cells at concentrations higher than 500 
µg/mL [119]. Thereby, in this study, the concentration range of 1-100 µg/mL nano-HA was 
selected to be tested in the more detailed study of the cell response of hMSCs to the 
nanoparticles. 
As already mentioned, the MSCs have the capacity of self-renewal and they are defined as 
a type of adult stem cells which contribute, in some circumstance, to the regeneration of 
mesenchymal tissues, once they have the potential for differentiation in multiple lineages, 
namely into osteogenic tissue [36, 42, 43]. The in vitro expansion of MSCs has been 
Chapter 5 
38 
 
extensively studied in this sense, since their use in tissue regeneration and engineering offers 
promising approaches for the therapy of a wide range of trauma and orthopaedic conditions 
[83]. It is known that nano-HA can influence the behaviour of bone-related cells [1-3, 69, 83, 
96]. Thereby, the effects of the nano-HA formulation NanoXIM•HAp102® on hMSCs were 
assessed for the viability/proliferation profile, apoptosis, cell morphology and pattern of cell 
growth, expression of osteoblastic genes and uptake of the nanoparticles throughout a period 
of 21 days.  
The MTT assay (figure 7), which is based in the reducing ability of metabolic active cells, 
showed time and dose-dependent effects of nano-HA. At day 7, i.e. one day after the 
addition of the particles, values showed a tendency for a dose-dependent increase in the 
metabolic activity, which is probably an attempt of the cells in coping with the changes that 
were imposed to their surroundings due to the presence of the nanoparticles. However, at 
longer exposure times, MTT assay assessed at day 14 showed a slight dose-dependent 
decrease in the cell metabolic activity/proliferation suggesting a deleterious effect of nano-
HA. Still, with the continuous exposure to the particles, cells were able to recover from this 
effect at the lower nano-HA levels (1 and 10 g/mL), as shown by the MTT assay at day 21; in 
addition, an inductive effect was even observed in the cultures grown in the presence of 10 
g/mL. Higher levels, ≥ 50 g/mL, caused decreased cell viability/proliferation. These 
observations are in line with previous studies showing dose-dependent effects of HA 
nanoparticels in the proliferation of MSCs, including increased proliferation in the presence of 
nanophase hydroxyapatite particles at concentrations lower than 20 µg/mL [120]. In the 
present work, it is interesting to note that hMSCs were more sensitive to the deleterious 
effects of nano-HA compared to MG63 cells. This might be due to the different features of 
the two cell types, namely related with the more proliferative and uncontrolled growth of 
MG63 cells compared to that of MSCs [118]. 
The effect of nano-HA on the osteoblastic differentiation of hMSCs was investigated by 
histochemical staining for ALP and collagen (figures 8-10). ALP detection was habitually used 
as an early marker of osteoblast differentiation in vitro; moreover collagen was also widely 
used to evaluate the osteogenic differentiation of MSCs [46, 64]. Results showed that cells 
synthetized ALP and collagen and that the cell layer and the staining intensity increased with 
the culture time. In addition, it was observed that cells grew with a typical organization, 
namely forming cell clusters that increased progressively and stained intensively. This is a 
relevant finding, as it is known to be the normal pattern of cell growth of MSCs. Formation of 
cell clusters is an early and critical event leading to the osteoblastic differentiation and 
mineralization process [31, 121]. The presence of nano-HA did not affect this pattern of cell 
growth. However, it is worth to mention that the continuous exposure to nano-HA 10 µg/mL 
resulted in an increase in the amount of the cell layer and also in the staining intensity for 
ALP and collagen (mostly at day 21), suggesting an enhanced osteogenic differentiation of 
MSCs. On the other hand, in the presence of nano-HA 50 µg/mL deleterious effects were 
observed, reflected by a less abundant cell layer. 
SEM observation of the cultures showed that hMSCs were able to attach, spread and 
proliferate, in control and in the presence of nano-HA, which is in agreement to that 
observed in the histochemical staining and with results of cell  morphology  and F-actin 
cytoskeletal organization. Cells also display the typical elongated/polygonal morphology of 
the MSCs with long cytoplasmic projections, and a cell layer with abundant cellular 
interactions (figure 11). SEM images also showed that the nano-HA organized as micrometric 
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aggregates that appeared to present a high affinity to the cell layer (figures 11 to 13). These 
aggregates were found in association or in close proximity with the spread cells, and they 
also appeared to be localized inside the cells (figure 13). EDS spectra of the aggregates 
confirm the elemental composition of nano-HA, showing the Ca and P peaks.  
By using TEM analyses, it was found that nano-HA has a close interaction with the cell 
membrane and followed an internalization process by an endocytosis pathway, as expected 
for the uptake of nanoparticles [5, 68, 104, 106-108]. Thereby nano-HA was present in the 
intracellular environment located in varying size lysosomic vesicles. Moreover, TEM images 
showed suggested a dose-dependent uptake, as the cultures exposed to nano-HA 50 µg/mL 
presented a higher amount of internalized particles compared to that seen in the cultures 
exposed to nano-HA 10 µg/mL. Images also show some degradation/dissolution within the 
acidic environment of the lysosomes. It has been reported that this process might cause an 
increase of the levels of Ca2+ in the cytoplasm, modulating the cellular behaviour, due to the 
known role of calcium ions in a variety of intracellular pathways. Appropriate levels of Ca2+ 
might be favourable for the osteoblastic proliferation and differentiation [109]. However, 
previous studies have also suggested that increases in intracellular calcium may promote 
apoptosis [68, 122, 123]. Related to this, in the present work, TEM images of the cultures 
exposed to nano-HA 50 µg/mL show the presence of cells displaying typical apoptotic signs 
(figure 15F). Also, the evaluation of caspase-3 in the cultures (figure 16) showed increased 
amount of this enzyme in the presence of the higher nano-HA concentrations (50 and 100 
µg/mL).  
The effect of nano-HA on hMSCs osteogenic differentiation was assessed by PCR analysis 
regarding the gene expression of osteoblastic-related proteins, such as Runx2, Col I, ALP, 
BMP-2 and OPG. Both control cultures and cultures exposed to nano-HA expressed these 
genes, all of them involved in the osteoblastic differentiation pathway. Runx2 is responsible 
for inducing the osteogenic phenotype at an early stage and also to inhibit the differentiation 
of MSCs into adipocytes and chondrocytes [13, 65, 67, 69]. Collagen is the main component of 
the bone extracellular matrix synthesized by osteoblast lineage cells, and has been 
considered an early bone differentiation marker, which has a role in osteoblast 
differentiation [31]. ALP is an early osteoblastic differentiation marker widely used to 
evaluate the in vitro osteogenic differentiation of MSCs [75]. BMP-2 is known to participate in 
the regulation of cell growth and differentiation, along with the induction of osteogenic 
progenitor cells in bone defect sites during the healing process [67, 124]. Furthermore BMP-2 
and wingless-ints (Wnts) pathways together have a critical role in promote Runx2 expression 
to promote osteoblast differentiation [13, 69]. Regarding OPG, this molecule has a key role in 
the cell-to-cell communication between the osteoblasts and the osteoclasts during the bone 
remodelling, and it is known to be a negative regulator of osteoclastogenesis [67, 76]; 
however, its role in osteoblast differentiation is still unclear. But more recently Yu et al. 
(2011) showed that OPG expression is associated with preosteoblast maturation and promotes 
matrix maturation [76]. Nano-HA, at 10 and 50 g/mL, did not cause statistically significant 
effects in the expression of Runx2, Col I and OPG. Still, nano-HA clearly had an inductive 
effect in the expression of BMP-2. Nevertheless, ALP expression was slightly decreased in the 
presence of nano-HA 50 g/mL. 
Overall, results showed that nano-HA display a low cytotoxicity profile. Only high levels of 
nano-HA, similar and higher than 50 g/mL caused slightly deleterious effects on the cell 
metabolic activity/proliferation, amount of apoptosis and expression of ALP. On the other 
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hand, the presence of 10 g/mL resulted in a slight inductive effect on the cell metabolic 
activity/proliferation and expression of BMP-2. These observations are in line with the 
reported studies showing low cytotoxicity of HA nanoparticles towards osteoblastic cells, and 
also their ability to modulate cell proliferation and differentiation events. Thus, upon 
exposure to nano-HA, increased proliferation was found in bone marrow-derived 
mesenchymal stem cells [120] and enhanced osteoblastic differentiation features was also 
observed for these cells [120,125], and also for the osteoblastic cell lines hFOB [107] and 
MG63[119]  However, these studies show a great variability of results, which is expected 
considering the wide versatility and diversity of the physicochemical properties of the tested 
particles, the cell system and the experimental protocols. 
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Conclusion 
In this thesis, the dose-dependent effect of the nano-HA formulation NanoXIMHap102® 
was evaluated regarding the proliferation and osteogenic differentiation of hMSCs.  
In control conditions (absence of nano-HA), hMSCs proliferated throughout a 21-day 
culture time, presenting the expected cellular organization for mesenchymal stem cells, 
namely the formation of cell clusters scattered over the culture substratum. On SEM 
observation, they showed an elongated/polygonal morphology with abundant cell-to-cell 
contact. Cultures display a positive staining for ALP and collagen, which increased with the 
culture time, and expressed the osteoblastic-related genes Runx2, ALP, collagen, BMP-2 and 
OPG. 
TEM analyses revealed that nano-HA was readily internalized by hMSCs by endocytosis. 
Nano-HA aggregates were seen in varying size lysosomes and showed low intracellular 
dissolution rate. The presence of nano-HA in hMSCs cultures, in the range 1 - 50 µg/mL, 
caused negligible effects in the cell behavior. In addition, exposure to nano-HA at 10 µg/mL 
resulted in an increase in the cell viability/proliferation, accompanied by the synthesis of ALP 
and collagen, and a normal F-actin cytoskeleton organization, without any increase in the 
apoptosis rate. Moreover, hMSCs presented increased expression of BMP-2, an important 
osteogenic differentiation marker. The presence of higher nano-HA levels (50 and 100 g/mL) 
were associated with slight deleterious effects in the measured cell response parameters.  
These data contribute to further understanding of the functional properties of the nano-
HA formulation NanoXIM•HAp102®. Accordingly, nano-HA was able to modulate the 
proliferation and osteoblastic differentiation of hMSCs. At selected conditions, nano-HA 
exhibits an interesting profile for bone tissue applications. 
 42 
 
 43 
 
References 
[1] Cardoso D A, Jansen J A, Leeuwenburgh S C G, Synthesis and application of 
nanostructured calcium phosphate ceramics for bone regeneration. J Biomed Mater 
Res B Appl Biomater, 2012, 100, 2316-2326. 
[2] Zhang L, Webster T J, Nanotechnology and nanomaterials: Promises for improved 
tissue regeneration. Nanotoday, 2009, 4, 66–80. 
[3] Fox K, Tran P A, Tran N, Recent Advantages in Research Applications of Nanophase 
Hydroxyapatite. ChemPhysChem2, 2012, 13, 2495–2506. 
[4] Hench L L, Wilson J, An Introduction to Bioceramics, World Scientific Publishing Co 
Pte Ltd, Chap. 9, 1993. 
[5] Silva V M T M, Quadros P A, Laranjeira P E M S C, Dias M M, Lopes J C B, A Novel 
Continuous Industrial Process for Producing Hydroxyapatite Nanoparticles, Journal 
of Dispersion Science and Technology, V. 29, pp. 542–547, 2008. 
[6] Fluidinova,http://www.fluidinova.com/products/nanoxim-med/nanoxim-
hap100/hydroxyapatite-nanoparticles-pastes-for-use-inmedical-applications/62/, 
Accessed 10 October 2012.  
[7] Blitterswijk C V, Tissue Engineering, Ed. 1st, Chap. An introduction, Academic Press, 
2007. 
[8] Saltzman W M, Tissue Engineering: Engineering Principles for the Design of 
Replacement Organs and Tissues. OUP USA, 2004, 5-16. 
[9] GrifÞth L G, Naughton G, Tissue Engineering-Current Challenges and Expanding 
Opportunities. Science, 2002, 295, 1009-1013. 
[10] Dorozhkin S V, Calcium Orthophosphates in Nature, Biology and Medicine. Materials, 
2009, 2, 399-498. 
[11] Mellon S J, Tanner K E, Bone and its adaptation to mechanical loading: a review. 
International Materials Reviews, 2012, 57, 235-255. 
[12] Pina S, Cements of doped calcium phosphates for bone implantation, Universidade 
de Aveiro, Ph.D.Thesis, Aveiro, 2009. 
[13] Datta H K, Ng W F, Walker J A, Tuck S P, Varanasi S S, The cell biology of bone 
metabolism. J Clin Pathol, 2008, 61, 577-587. 
[14] Blair H C, Zaidi M, Schlesinger P H, Mechanisms balancing skeletal matrix synthesis 
and degradation. Biochem J., 2002, 364, 329-341. 
[15] Laranjeira M S, Preparation and characterization of porous 3D Bonelike® structures 
through biomodelling and 3D machining techniques, Faculdade de Engenharia da 
Universidade do Porto, Master thesis, Porto, 2006. 
[16] Wopenka B, Pasteris J D, A mineralogical perspective on the apatite in bone. 
Materials Science and Engineering, 2005, 25, 131–143. 
 44 
 
[17] Karlson M, Nano-porous alumina a potencial bone implant coating, Uppsala 
University, Ph.D.Thesis, Uppsala, 2004. 
[18] Tortora G, Principles of anatomy and physiology, 11th Ed, Chap. 6, New Jersey: J. 
Wiley: Hoboken, 2006. 
[19] Sousa J P, Efeito das BMPs na regeneração óssea: mecanismo de acção e aplicação 
em Medicina Dentária, Faculdade de Medicina Dentária da Universidade do Porto, 
Dissertação de Mestrado, Porto, 2011. 
[20] Mateus A Y P, Development, Characterisation and Application of Calcium Phosphates 
Nanocrystals Aggregates in a Collagen Matrix to be used as Biomaterial in Bone 
Regeneration, Faculdade de Engenharia da Universidade do Porto, Master thesis, 
Porto, 2010. 
[21] Downey P A, Siegel M I, Bone Biology and the Clinical Implications for Osteoporosis. 
Physical Therapy, 2006, 86, 77-91. 
[22] Buckwalter J A, Glimcher M J, Cooper RR, Becker R, Bone biology, part I: structure, 
blood supply, cells, matrix, and mineralization. Cap. 4-7, Academic Press, 1996. 
[23] Arnett T, Henderson B, Methods in Bone Biology. Ed. 1 st, Chap. 1, Springer, 1997. 
[24] Seibel M J., Robins S P., Bilezikia J P, Dynamics of Bone and Cartilage Metabolism: 
Principles and Clinical Applications, Ed 2 nd, Chap. 4 and 14, Academic Press, 2006.   
[25] Marks S, Popoff S, Bone cell biology: the regulation of development, strucutre and 
function in the skeleton. American Journal of Anatomy, 1988, 183, 1–44. 
[26] Holtrop M E, Light and electron microscopic structure of bone forming cells. Telford 
Press Inc, 1, 1–39, 1990. 
[27] Lian J B, Stein G S, Development of the osteoblast phenotype: molecular 
mechanisms mediating osteoblast growth and differentiation. Iowa Orthop J, 1995, 
15, 118–140. 
[28] Frost H M, Dynamics of bone remodeling. Bone Biodynamics, 1964, 315–33. 
[29] Bronner F, Farach-Carson M C, Rubin J, Bone Resorption (Topics in Bone Biology), 
Ed. 1st, Vol 2, Chap. 4, Springer, 2005. 
[30] Bonnick S L, Bone Densitometry in Clinical Practice, Ed. 3rd, Cap 2, Humana Press, 
2009. 
[31]  Bilezikian J P, Raisz L G, Martin T J, Principles of Bone Biology,Ed 2 nd, Vol.1, 
Academic Press, 2002.   
[32] Davies J E, Understanding Peri-Implant Endosseous Healing. Journal of Dental 
Educatio, 2005, 67, 932-949. 
[33] Sela J J, Bab I A, Principles of Bone Regeneration, Ed. 1st, Chap. 1, Springer, 2012.  
[34] Lieberman J R, Friedlaender G E, Bone Regeneration and Repair: Biology and 
Clinical Applications, Ed. 1st, Chap.2, Humana Press, 2005. 
[35] Braddock M, Houston P, Campbell C, Ashcroft P. Born again bone: Tissue 
engineering for bone repair. News Physiol. Sci., 2001, 208-213.  
[36] Nolta J A, Genetic Engineering of Mesenchymal Stem Cells, Chap. 1, Springer, 2006 
[37] Atala A, Lanza B, Methods of Tissue Engineering, Chap. 26, Academic Press Inc, 
2001. 
[38] Bajada S, Mazakova I, Ashton B A, Richardson J B, Ashammakhi N, Stem Cells in 
Regenerative Medicine: Topics in Tissue Engineering. Vol. 4, Chap. 13, F Chiellini, 
2008. 
 45 
 
[39] Marshak D R, Gardner R L, Gottlieb D, Stem Cell Biology, Chap. 16, Cold Spring 
Harbor Press, 2001. 
[40] Beresford J N, Owen M E, Marrow Stromal Cell Culture, Cambridge University Press, 
1998. 
[41] Amaral I, Chitosan Matrices for Cell-based Bone Regenerative Therapies, Faculdade 
de Engenharia da Universidade do Porto, Ph.D.Thesis, Porto, 2005. 
[42] Watt F M, Driskell R R, The therapeutic potential of stem cells, Phil. Trans. R. Soc. 
B, 2010, 365, 155–163.  
[43] Turksen K, Adult and Embryonic Stem Cells, Chap. 2, Humana Press, 2012. 
[44] Meyer U, Meyer T, Handschel J, Wiesmann H P, Fundamentals of Tissue Engineering 
and Regenerative Medicine, Chap. 41, Springer, 2009.  
[45] Coelho M J, Fernandes M H, Human bone cell cultures in biocompatibility testing. 
Part II: effect of ascorbic acid, β-glycerophosphate and dexamethasone on 
osteoblastic differentiation. Biomaterials, 2000, 21, 1095-1102. 
[46] Bhattacharya N, Stubblefield P, Frontiers of Cord Blood Science, Chap. 5, Springer, 
2009. 
[47] Komori T, Regulation of Osteoblast Differentiation by Transcription Factors. Journal 
of Cellular Biochemistry, 2006, 99, 1233–1239. 
[48] Jacobi A, Rauh J, Bernstein P, Liebers C, Zou X,  Comparative analysis of reference 
gene stability in human mesenchymal stromal cells during osteogenic 
differentiation. Biotechnology Progress, 2013. 
[49] Neve A, Corrado A, Cantatore F P, Osteoblast physiology in normal and pathological 
conditions. Cell Tissue Res, 2011, 343, 289–302. 
[50] Deng Z L, Sharff K A, Tang N et al. Regulation of osteogenic differentiation during 
skeletal development. Frontiers in Bioscience, 2008, 13, 2001-21. 
[51] Komori T, Regulation of Skeletal Development by the Runx Family of Transcription 
Factors. Journal of Cellular Biochemistry, 2005, 95, 445–453. 
[52] Fisher J P, Tissue Engineering Advances in Experimental Medicine and Biology. Ed. 1 
st, 433-438, Springer, 2007. 
[53] Kassem M, Abdallah BM, Saeed H, Osteoblastic cells: differentiation and trans-
differentiation. Arch Biochem Biophys, 2008, 473, 183–187. 
[54] Kulterer B, Friedl G, Jandrositz A, Sanchez-Cabo F, Prokesch A, Paar C, Scheideler 
M, Windhager R, Preisegger KH, Trajanoski k, Gene expression profiling of human 
mesenchymal stem cells derived from bone marrow during expansion and osteoblast 
differentiation. BMC Genomics, 2007, 8, 70-82. 
[55] Roman-Roman S, Garcia T, Jackson A, Theilhaber J, Rawadi G, Connolly T, Spinella-
Jaegle S, Kawai S, Courtois B, Bushnell S, Auberval M, Call K, Barona R, 
Identification of genes regulated during osteoblastic differentiation by genome-wide 
expression analysis of mouse calvaria primary osteoblasts in vitro. Bone 2003, 32, 
474–482. 
[56] Birmingham E, Niebur G L, McHugh P E, Shaw G, Barry F P,  McNamara L M, 
Osteogenic differentiation of mesenchymal stem cells is regulated by osteocyte and 
osteoblast cells in a simplified bone niche. Eur Cell Mater, 2012, 23, 13-27. 
[57] Yu H, Vos P, Ren Y, Overexpression of osteoprotegerin promotes preosteoblast 
differentiation to mature osteoblasts. Angle Orthodontist, 2011, 81, 100-106. 
[58] Logan J, Edwards K, Saunders N, Real-time PCR: Current Technology and 
Applications. Ed. 1 st, Chapter 9, Caister Academic Press, 2009. 
[59] Bagasra O, Hansen J, In-Situ PCR Techniques. Ed. 1 st, Chapter 1, Wiley-Liss, 1997. 
[60] Mullis K B, Faloona F A, Specific synthesis of DNA in vitro via a polymerase catalysed 
chain reaction. Methods Enzymol, 1987, 155, 335-50. 
 46 
 
[61] Peake I, The polymerase chain reaction. J Clin Pathol, 1989, 42, 673-676. 
[62] Lynch J R, Brown J M, The polymerase chain reaction: current and future clinical 
applications. Med Genet, 1990, 27, 2-7. 
[63] Andersen C L, Jensen J L, Ørntoft T F, Normalization of Real-Time Quantitative 
Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to 
Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data 
Sets. Cancer Research, 2004, 64, 5245–5250. 
[64] Tristan C, Shahani N, Sedlak T W, Sawa A, The diverse functions of GAPDH: Views 
from different subcellular compartments. Cellular Signalling, 2011, 23, 317–323. 
[65] Chen H, Zeng Y, Liu W, Zhao S, Wu J, Du Y, Multifaceted applications of 
nanomaterials in cell engineering and therapy. Biotechnol Adv, 2012. 
[66] McMahon R E, Wang L, Skoracki R, Mathur A B, Development of nanomaterials for 
bone repair and regeneration. J Biomed Mater Res Part B, 2013, 101, 387–397. 
[67] Webster T J, Ergun C, Doremus R H, Siegel R W, Bizios R, Enhanced osteoclast-like 
cell functions on nanophase ceramics. Biomaterials, 2001, 22, 1327–1333. 
[68] Motskin M, Wright D M, Muller K, Kyle N, Gard T G, Porter A E , Skepper J N, 
Hydroxyapatite nano and microparticles: Correlation of particle properties with 
cytotoxicity and biostability. Biomaterials, 2009, 30, 3307–3317. 
[69] Ferraz M P, Monteiro F J, Manuel C M, Hydroxyapatite nanoparticles: A review of 
preparation methodologies. Journal of Applied Biomaterials & Biomechanics, 2004, 
2, 74-80. 
[70] Liou S, Chen S, Liu D, Synthesis and characterization of needlelike apatitic 
nanocomposite with controlled aspect ratios. Biomaterials, 2003, 24, 3981–3988. 
[71] Webster T J, Siegel R W, Bizios R, Osteoblast adhesion on nanophase ceramics. 
Biomaterials, 1999, 20, 1221–1227. 
[72] Guo X, Gough J E, Xiao P, Liu J, Shen Z, Fabrication of nanostructured 
hydroxyapatite and analysis of human osteoblastic cellular response. J Biomed 
Mater Res A, 2007, 82, 1022-32. 
[73] Webster T J, Ergun C, Doremus R H, Siegel R W, Bizios R, Specific proteins mediate 
enhanced osteoblast adhesion on nanophase ceramics. J Biomed Mater Res, 2000, 
51, 475-48. 
[74] Gomes P J, Silva V M T M, Quadros P A, Dias M M,  Lopes, J C B, A Highly 
Reproducible Continuous Process for Hydroxyapatite Nanoparticles Synthesis. J 
Nanosci Nanotechnol, 2009, 9, 3387-95. 
[75] Brown P W, Calcium Phosphates in Biomedical Engineering. Encyclopedia of 
Materials: Science and Technology, 2001, 893–897. 
[76] Hench L L, Wilson J, An Introduction to Bioceramics, World Scientific Publishing Co 
Pte Ltd, Chap. 9, 1993. 
[77] Uskokovic´ V, Uskokovic´D P, Nanosized hydroxyapatite and other calcium 
phosphates: Chemistry of formation and application as drug and gene delivery 
agents. J Biomed Mater Res B Appl Biomater, 2011, 96, 152-91. 
[78] White A A, Production and characterization of hydroxyapatite/ multi-welled carbon 
nanotube composites. Clare college University of Cambridge, Ph.D. Thesis, 
Cambridge, 2009. 
[79] Poinern G E, Brundavanam R K, Mondinos N, Jiang Z T, Synthesis and 
characterisation of nanohydroxyapatite using an ultrasound assisted method. 
Ultrason Sonochem, 2009, 16, 469–474. 
 47 
 
[80] Legeros R Z, Biodegradation and bioresorption of calcium phosphate ceramics. Clin 
Mater, 1993, 14, 65–88. 
[81] Zhou H, Lee J, Nanoscale hydroxyapatite particles for bone tissue engineering. Acta 
Biomaterialia, 2011, 7, 2769–2781. 
[82] Dolatshahi-Pirouz A, Jensen T, Foss M, Chevallier J, Besenbacher F, Enhanced 
Surface Activation of Fibronectin upon Adsorption on Hydroxyapatite. Langmuir, 
2009, 25, 2971-2978.  
[83] Cai Y, Liu Y,Yan W,Hu Q, Tao J, Zhang M, Shic Z, Tang R, Role of hydroxyapatite 
nanoparticle size in bone cell proliferation. J Mater Chem, 2007, 17, 3780–3787. 
[84] Balasundarama G, J. Webster T J, A perspective on nanophase materials for 
orthopedic implant applications. J Mater Chem, 2006, 16, 3737–3745. 
[85] Rhee S, Synthesis of hydroxyapatite via mechanochemical treatment. Biomaterials, 
2002, 23, 1147–1152. 
[86] Bouyer E, Gitzhofer F, Boulos MI, Morphological study of hydroxyapatite nanocrystal 
suspension. J Mater Sci Mater Med, 2000, 11, 523-31. 
[87] Afshara A,  Ghorbania M, Ehsania N, Saeria M R, Sorrell C C, Some important factors 
in the wet precipitation process of hydroxyapatite. Materials and Design, 2003, 24, 
197–202. 
[88] Santos M H, Oliveira M, Souza L P F,Mansur H S, Vasconcelos W L, Synthesis Control 
and Characterization of Hydroxyapatite Prepared by Wet Precipitation Process. 
Materials Research, 2004, 7, 625-630. 
[89] Lopes J C B, Laranjeira P E M S C, Dias M M Q. Martins A A A, Network Mixer and 
Related Mixing Process. WO Patent 2005/077508. 
[90] Fluidinova, http://www.fluidinova.com/main.php?id=32, Accessed 16 January 
2013.  
[91] Faria R P V, Estudo e Optimização do Processo Industrial de Produção de 
Hidroxiapatite Recorrendo à Tecnologia NETmix®. Faculdade de Engenharia da 
Universidade do Porto, Master thesis, Porto, 2008. 
[92] Laranjeira P E M S C, NETmix® Static Mixer- Modeling, CDF Simulation and 
Experimental Chatacterisation. Faculdade de Engenharia da Universidade do Porto, 
Ph.D. Thesis, Porto, 2005. 
[93] Correia Daniela, Production of Hydroxyapatite Nanoparticles for Cosmetic and 
Orthopaedic Applications: Effect of Chelants and Dispersants. Faculdade de 
Engenharia da Universidade do Porto, Master thesis, Porto, 2008. 
[94] Rodrigues M F B, Doping of Hydroxyapatite Nanoparticles with Metal Ions for 
Biomedical, Orthopaedic and Dentistry Applications. Faculdade de Engenharia da 
Universidade do Porto, Master thesis, Porto, 2008. 
[95] Kalita S J, Bhardwaj A, Bhatt H A, Nanocrystalline calcium phosphate ceramics in 
biomedical engineering. Materials Science and Engineering C, 2007, 27, 441–449. 
[96] Puleo D A, Nanci A, Understanding and controlling the bone-implant interface. 
Biomaterials, 1999, 20, 2311-2321. 
[97] Kumta, P N, Sfeir C, Lee D-H, Nanostructured calcium phosphates for biomedical 
applications: novel synthesis and characterization. Acta Biomaterialia, 2005, 1, 65-
83. 
 48 
 
[98] Phillips M J, Darr J A, Luklinska Z B, Rehman I, Synthesis and characterization of 
nano-biomaterials with potential osteological applications. J Mater Sci Mater Med, 
2003, 14, 875-82. 
[99] Huang S B, Gao S S, Yu H Y, Effect of nano-hydroxyapatite concentration on 
remineralization of initial enamel lesion in vitro. Biomed. Mater, 2009, 4, 1-6. 
[100] Wu H-C, Wang T-W, Sun J-S, Wang W-H, Lin F-H, A novel biomagnetic nanoparticle 
based on hydroxyapatite. Nanotechnology, 2007, 18, 165601-165609. 
[101] Tran N, Webster T J, Nanotechnology for bone materials. Wiley Interdiscip. Rev. 
Nanomed. Nanobiotechnol, 2009, 1, 336–351.   
[102] Tran N, Webster T J, Increased osteoblast functions in the presence of 
hydroxyapatite-coated iron oxide nanoparticles Acta Biomater, 2011, 7, 1298-306. 
[103] Tran N, Webster T J, Magnetic nanoparticles: biomedical applications and 
challenges. J Mater Chem, 2010, 20, 8760–8767. 
[104] Verma A, Stellacci F, Effect of Surface Properties on Nanoparticle–Cell Interactions. 
Small, 2010, 6, 12–21. 
[105] Webster T J, Nanophase ceramics: The future orthopedic and dental implant 
materials. Adv Chem Eng, 2001, 27, 125–166. 
[106] Bauer I W, Li S-P, Han Y-C, Yuan L, Jin M-Z, Internalization of hydroxyapatite 
nanoparticles in liver cancer cells. J Mater Sci Mater Med., 2008, 19, 1091-5.  
[107] Xu J L, Khor K A, Sui J J, Zhang J H, Chen W N, Protein expression profiles in 
osteoblasts in response to differentially shaped hydroxyapatite nanoparticles. 
Biomaterials, 2009, 30, 5385-5391. 
[108] Shi Z, Huang X, Cai Y, Tang R, Yang D. Size effect of hydroxyapatite nanoparticles 
on proliferation and apoptosis of osteoblast-like cells. Acta Biomaterialia, 2009, 5, 
338-345. 
[109] Maeno S, Niki Y, Matsumoto H, Morioka H, Yatabe T, Funayama A, The effect of 
calcium ion concentration on osteoblast viability proliferation and differentiation in 
monolayer and 3D culture. Biomaterials, 2005, 26, 4847–55. 
[110] Elmore S, Apoptosis: A Review of Programmed Cell Death. Toxicologic Pathology, 
2007, 35, 495–516.  
[111] Kerr J F R, Whyllie A H, Currie A R, Apoptosis: A basic biological phenomenon with 
wide-ranging implications in tissue kinetics. Br. J. Cancer, 1972, 26, 239-257. 
[112] Watanabe M, Hitomi M, van der Wee K, Rothenberg F, Fisher S A, Zucker R, Svoboda 
K K, Goldsmith E C, Heiskanen K M, Nieminen A L, The pros and cons of apoptosis 
assays for use in the study of cells, tissues, and organs. Microsc Microanal, 2002, 8, 
375-91. 
[113] Haunstetter A, Izumo S. Apoptosis: basic mechanisms and implications for 
cardiovascular disease. Circ Res. 1998, 82, 1111-29. 
[114] Lincz L F, Deciphering the apoptotic pathway: All roads lead to death. Immunology 
and Cell Biology, 1998, 76, 1-19.  
[115] Porter A G, Jänicke R U. Emerging roles of caspase-3 in apoptosis. Cell Death Differ, 
1999, 6, 99-104. 
[116] Nicholson D W, Ali A, Thornberry N A, Identification and inhibition of the ICE/CED-3 
protease necessary for mammalian apoptosis. Nature, 1995, 43,  376-7. 
[117] Hattar S, Berdal A, Asselin A, Loty S, Greenspan D C, Sautier J M; Behaviour of 
moderately differentiated osteoblast-like cells cultured in contact with bioactive 
glasses. European Cells and Materials, 2002, 4, 61-69. 
 49 
 
[118] Czekanska E M, Stoddart M J, Richards R G, Hayes J S; In search of an osteoblast cell 
model for in vitro research. European Cells and Materials, 2012, 24, 1-17. 
[119] Santos C, Gomes P S, Duarte J A, Franke R, Almeida M M, Costa M E V, M H, 
Fernandes; Relevance of the sterilization-induced effects on the properties of 
different hydroxyapatite nanoparticles and assessment of the osteoblastic cell 
response. Journal of the Royal Society Interface, 2012, 9, 3397-3410. 
[120] Liu Y, Wang G, Cai Y, Ji H, Zhou G, Zhao X, Tang R, Zhan M; In vitro effects of 
nanophase hydroxyapatite particles on proliferation and osteogenic differentiation 
of bone marrow-derived mesenchymal stem cells. Journal of Biomedical Materials 
Research Part A, 2008, 1083-1091. 
[121] Gao Y, Cao W-L, Wang X-Y, Gong Y-D, Tian J-M Zhao N-M, Zang X-F; 
Characterization and osteoblast-like cell compatibility of porous scaffolds: bovine 
hydroxyapatite and novel hydroxyapatite artificial bone. J Mater Sci Mater Med, 
2006, 17, 815–823. 
[122] Yu S P, Canzoniero L M T, Choi D W; Ion homeostasis and apoptosis. Curr Opin Cell 
Biol, 2001,13, 405–411. 
[123] Wang L, Zhou G, Liu H, Niu X, H J, Zhengac L, Fan Y; Nano-hydroxyapatite particles 
induce apoptosis on MC3T3-E1 cells and tissue cells in SD rats. Nanoscale, 2012, 4, 
2894–2899. 
[124] Kim K, Dean D, Lu A, Mikos A G, Fisher J P, Early osteogenic signal expression of rat 
bone marrow stromal cells is influenced by both hydroxyapatite nanoparticle 
content and initial cell seeding density in biodegradable nanocomposite scaffolds. 
Acta Biomaterialia, 2011, 7, 1249–1264. 
[125] Gonzalez-McQuire R, Green D W, Partridge K A, Oreffo R O C, Mann S, Davis S A; 
Coating of Human Mesenchymal Cells in 3D Culture with Bioinorganic Nanoparticles 
Promotes Osteoblastic Differentiation and Gene Transfection Advanced Materials, 
2007, 19, 2236-2240. 
 50 
 
Annex 1  
Technical datasheet of NanoXIM•Hap102® 
 
 
 51 
 
 
 
 
 
 
 
 52 
 
 
